{"extracted text":"Morbidity and Mortality Weekly Report Weekly / Vol. 66 / No. 45 No vember 17, 2017 INSIDE 1248 CDC Gr and Rounds: Improving Medication Adherence for Chronic Disease Management  Innovations and Opportunities 1252 Global R outine Vaccination Coverage, 2016 1256 P rogress in Rubella and Congenital Rubella Syndrome Control and Elimination  Worldwide, 20002016 1261 Announcement 1263 QuickStats Continuing Education examination available at https: //www. cdc. gov/mmwr/cme/conted_info. html#weekly. U. S. Department of Health and Human ServicesCenters for Disease Control and PreventionDisparities in State-Specific Adult Fruit and Vegetable Consumption  United States, 2015 Seung Hee Lee-Kwan, PhD1; Latetia V. Moore, PhD1; Heidi M. Blanck, PhD1; Diane M. Harris, PhD1; Deb Galuska, PhD1 The 20152020 Dietary Guidelines for Americans recommend that Americans consume more fruits and vegetables as part of an overall dietary pattern to reduce the risk for diet-related chronic diseases such as cardiovascular disease, type 2 diabetes, some cancers, and obesity (1) . Adults should consume 1. 52. 0 cup equivalents of fruits and 2. 03. 0 cups of vegetables per day. * Overall, few adults in each state met intake recommendations according to 2013 Behavioral Risk Factor Surveillance System (BRFSS) data; however, sociodemographic characteristics known to be associated with fruit and vegetable consumption were not examined (2) . CDC used data from the 2015 BRFSS to update the 2013 report and to estimate the percentage of each states population meeting intake recom-mendations by age, sex, race/ethnicity, and income-to-poverty ratio (IPR) for the 50 states and District of Columbia (DC) . Overall, 12. 2% of adults met fruit recommendations rang - ing from 7. 3% in West Virginia to 15. 5% in DC, and 9. 3% met vegetable recommendations, ranging from 5. 8% in West Virginia to 12. 0% in Alaska. Intake was low across all socio - economic groups. Overall, the prevalence of meeting the fruit intake recommendation was highest among women (15. 1%), adults aged 3150 years (13. 8%), and Hispanics (15. 7%); the prevalence of meeting the vegetable intake recommendation was highest among women (10. 9%), adults aged 51 years (10. 9%), and persons in the highest income group (11. 4%) . Evidence-based strategies that address barriers to fruit and vegetable consumption such as cost or limited availability could improve consumption and help prevent diet-related chronic disease. BRFSS conducts an annual, state-based, random-digit dialed landline and cellular telephone household survey of * A ppropriate for adults who engage in <30 minutes of moderate physical activity; more active adults might be able to consume more while staying within calorie needs. https: //www. choosemyplate. gov/fruit; https: //www. choosemyplate. gov/vegetables. noninstitutionalized, civilian U. S. adults aged 18 years to col - lect data on health and health risk behaviors related to chronic disease. BRFSS uses a complex multistage cluster sampling design and weights by iterative proportional fitting to adjust for nonresponse, noncoverage, and selection bias (3) . In 2015, BRFSS asked six questions to assess how many times per day, week, or month the participants consumed 1) 100% fruit juice, 2) whole fruit, 3) dried beans, 4) dark green vegetables, 5) orange vegetables, and 6) other vegetables, during the previous month. Daily frequency of intake was calculated by dividing reported intake by 7 for intake reported by week, and by 30 for intake reported by month. To estimate the percentage of each states population meeting fruit and vegetable intake recommendations by demographic characteristics, previously developed scoring algorithms derived from the National Health and Nutrition Examination Survey (NHANES) were used to predict whether a respondent met fruit and vegetable recommendations for their age and sex based on the number of times per day they reported consuming fruits and vegetables Morbidity and Mortality Weekly Report1242 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and PreventionThe MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U. S. Department of Health and Human Services, Atlanta, GA 30329-4027. Suggested citation: [Author names; first three, then et al. , if more than six. ] [Report title]. MMWR Morb Mortal Wkly Rep 2017; 66: [inclusive page numbers]. Centers for Disease Control and Prevention Brenda Fitzgerald, MD, Director William R. Mac Kenzie, MD, Acting Associate Director for Science Joanne Cono, MD, ScM, Director, Office of Science Quality Chesley L. Richards, MD, MPH, Deputy Director for Public Health Scientific Services Michael F. Iademarco, MD, MPH, Director, Center for Surveillance, Epidemiology, and Laboratory Services MMWR Editorial and Production Staff (Weekly) Sonja A. Rasmussen, MD, MS, Editor-in-Chief Charlotte K. Kent, PhD, MPH, Executive Editor Jacqueline Gindler, MD, Editor Teresa F. Rutledge, Managing Editor Douglas W. Weatherwax, Lead T echnical Writer-Editor Soumya Dunworth, PhD, Kristy Gerdes, MPH, Teresa M. Hood, MS, T echnical Writer-EditorsMartha F. Boyd, Lead Visual Information Specialist Maureen A. Leahy, Julia C. Martinroe, Stephen R. Spriggs, Tong Yang, Visual Information Specialists Quang M. Doan, MBA, Phyllis H. King, Paul D. Maitland, Terraye M. Starr, Moua Yang, Information T echnology Specialists MMWR Editorial Board Timothy F. Jones, MD, Chairman Matthew L. Boulton, MD, MPH Virginia A. Caine, MD Katherine Lyon Daniel, PhD Jonathan E. Fielding, MD, MPH, MBA David W. Fleming, MD William E. Halperin, MD, DrPH, MPH King K. Holmes, MD, PhD Robin Ikeda, MD, MPH Rima F. Khabbaz, MD Phyllis Meadows, PhD, MSN, RN Jewel Mullen, MD, MPH, MPAJeff Niederdeppe, PhD Patricia Quinlisk, MD, MPH Patrick L. Remington, MD, MPH Carlos Roig, MS, MA William L. Roper, MD, MPH William Schaffner, MDseparately, accounting for race/ethnicity and IPR (poverty defined according to federal poverty guidelines), updated with 2015 Poverty Guidelines for the 48 contiguous states and DC. IPR was calculated following the previous study methods (4) using the midpoint of reported household income for persons who reported their household income; household size was assumed to equal one for participants who did not report the number of persons residing in the household. Individual predicted probabilities of meeting recommendations were averaged to obtain sociodemographic-specific estimates. Intake recommendations were based on the 20152020 Dietary Guidelines for Americans (1) and used the ageand sex-specific recommendations for adults who engage in <30 minutes of moderate physical activity daily. BRFSS respondents race/ethnicity (Hispanic, non-Hispanic black [black], non-Hispanic white [white], and all others) and IPR (<1. 25, 1. 25%3. 49%, and >3. 49) were defined consistent with definitions in previous analyses (5) . Estimates for the racial/ethnic group other are not presented because of the small sample sizes and difficul-ties in providing meaningful interpretation, but are included in overall estimates and those by age, sex, and IPR. Among 441, 456 respondents, 122, 041 (28%) were excluded, including 5, 074 who did not reside in the 50 states or DC (because the scoring algorithm is derived from NHANES, which excluded territories), 58, 949 who did not answer all six questions on fruit and vegetable intake, 127 who had implausible values of  https: //aspe. hhs. gov/2015-poverty-guidelines. reported intake of fruit more than 16 times per day or veg - etables more than 23 times per day (4), and 55, 891 who had missing values for income, resulting in a final analytic sample of 319, 415. The median response rate for 2015 BRFSS was 47. 2% for the 50 states and DC (range = 33. 9%61. 1%) . T-tests were used to compare differences by demographic groups. Statistical analyses were performed to account for the complex survey design and nonresponse. Balanced repeated replication technique, replicate weights, and Taylor lineariza - tion were used to calculate standard errors and confidence intervals, consistent with the previous study (2) . In 2015, the median frequency of reported intake among all respondents was one time per day for fruit and 1. 7 times per day for vegetables (Table 1) . Among all respondents, 12. 2% met fruit intake recommendations, ranging from 7. 3% in West Virginia to 15. 5% in DC, and 9. 3% met vegetable intake recommendations, ranging from 5. 8% in West Virginia to 12. 0% in Alaska (Table 1) . Overall in 2015, the percentage of adults meeting fruit and vegetable recommendations varied by selected characteristics (Table 2) (Table 3) . A higher propor - tion of women met both fruit and vegetable recommenda - tions (15. 1% and 10. 9%, respectively) than did men (9. 2% and 7. 6%, respectively), and a higher proportion of women met recommendations in most states. By age group, young adults aged 1830 years accounted for the lowest proportion of persons meeting recommendations for fruit and vegetable  https: //www. cdc. gov/brfss/annual_data/2015/2015_responserates. html. Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1243 US Department of Health and Human Services/Centers for Disease Control and PreventionTABLE 1. Median frequencies and percentages of adults meeting federal fruit and vegetable intake recommendations per day, by state  Behavioral Risk Factor Surveillance System, United States and District of Columbia, 2015 Jurisdiction Sample sizeMedian daily intake frequency% of respondents (95% CI) meeting recommendations Fruit Vegetable Fruit intake Vegetable intake Overall 319, 415 1. 0 1. 7 12. 2 (11. 2-13. 3) 9. 3 (6. 1-12. 5) Alabama 5, 630 1. 0 1. 5 8. 8 (7. 3-10. 2) 6. 1 (2. 89. 4) Alaska 2, 944 1. 0 1. 8 12. 9 (10. 5-15. 2) 12. 0 (6. 6-17. 4) Arizona 5, 490 1. 0 1. 7 13. 2 (11. 4-15. 1) 10. 5 (6. 0-14. 9) Arkansas 3, 631 0. 9 1. 5 9. 5 (7. 5-11. 5) 7. 8 (3. 7-12. 0) California 9, 443 1. 1 1. 8 13. 6 (12. 0-15. 2) 11. 2 (7. 0-15. 4) Colorado 9, 530 1. 1 1. 8 13. 5 (11. 7-15. 3) 11. 6 (7. 6-15. 6) Connecticut 8, 491 1. 1 1. 7 13. 5 (11. 8-15. 1) 10. 4 (6. 8-13. 9) Delaware 2, 859 1. 0 1. 7 12. 5 (10. 4-14. 5) 8. 6 (5. 0-12. 1) District of Columbia 2, 814 1. 0 1. 9 15. 5 (12. 5-18. 6) 9. 7 (4. 7-14. 8) Florida 7, 152 1. 0 1. 7 14. 0 (12. 2-15. 8) 10. 3 (6. 7-13. 8) Georgia 3, 342 1. 0 1. 6 12. 0 (10. 1-13. 9) 8. 5 (4. 7-12. 4) Hawaii 5, 900 1. 0 1. 7 12. 4 (10. 6-14. 1) 11. 5 (7. 4-15. 6) Idaho 4, 616 1. 0 1. 8 11. 8 (9. 9-13. 6) 10. 8 (6. 9-14. 6) Illinois 4, 585 1. 0 1. 6 14. 0 (12. 1-15. 9) 9. 7 (5. 7-13. 7) Indiana 4, 596 1. 0 1. 5 11. 5 (9. 6-13. 4) 8. 6 (4. 5-12. 6) Iowa 4, 706 1. 0 1. 5 10. 7 (9. 0-12. 4) 7. 0 (3. 5-10. 6) Kansas 16, 780 1. 0 1. 6 10. 0 (8. 8-11. 2) 8. 1 (4. 8-11. 5) Kentucky 5, 074 1. 0 1. 5 8. 0 (6. 69. 5) 6. 3 (2. 4-10. 2) Louisiana 3, 293 0. 9 1. 4 11. 2 (9. 3-13. 0) 8. 3 (4. 6-12. 1) Maine 7, 447 1. 1 1. 7 14. 1 (12. 2-16. 0) 10. 7 (7. 3-14. 1) Maryland 8, 800 1. 1 1. 7 14. 0 (11. 9-16. 0) 9. 0 (5. 3-12. 7) Massachusetts 6, 198 1. 1 1. 7 14. 0 (12. 2-15. 7) 11. 1 (7. 3-14. 8) Michigan 6, 835 1. 0 1. 6 11. 9 (10. 3-13. 5) 7. 7 (4. 3-11. 1) Minnesota 12, 789 1. 0 1. 6 11. 6 (10. 2-13. 1) 8. 1 (4. 8-11. 4) Mississippi 4, 416 0. 9 1. 4 8. 7 (7. 1-10. 4) 6. 2 (2. 79. 7) Missouri 5, 326 1. 0 1. 6 10. 8 (9. 1-12. 4) 7. 7 (3. 9-11. 5) Montana 4, 528 1. 0 1. 7 10. 7 (8. 8-12. 5) 8. 3 (4. 5-12. 1) Nebraska 13, 771 1. 0 1. 6 11. 4 (9. 9-12. 9) 7. 9 (4. 2-11. 6) Nevada 2, 133 1. 0 1. 8 13. 1 (10. 5-15. 6) 11. 5 (7. 0-16. 0) New Hampshire 5, 005 1. 1 1. 8 14. 3 (12. 2-16. 4) 10. 8 (7. 2-14. 4) New Jersey 8, 207 1. 0 1. 6 12. 1 (10. 5-13. 8) 8. 3 (4. 7-11. 8) New Mexico 5, 166 1. 0 1. 7 12. 3 (10. 5-14. 0) 10. 3 (6. 1-14. 6) New York 9, 145 1. 0 1. 7 14. 0 (12. 4-15. 6) 9. 6 (5. 9-13. 2) North Carolina 4, 737 1. 0 1. 7 10. 4 (8. 9-12. 0) 8. 1 (4. 6-11. 6) North Dakota 3, 911 1. 0 1. 5 11. 9 (10. 0-13. 7) 7. 9 (3. 7-12. 0) Ohio 8, 495 1. 0 1. 6 10. 6 (9. 0-12. 2) 6. 9 (3. 3-10. 5) Oklahoma 5, 177 1. 0 1. 6 8. 0 (6. 69. 5) 6. 1 (2. 69. 6) Oregon 3, 848 1. 0 1. 9 13. 4 (11. 4-15. 4) 11. 9 (8. 0-15. 8) Pennsylvania 4, 287 1. 0 1. 6 11. 7 (9. 9-13. 5) 8. 4 (4. 6-12. 1) Rhode Island 4, 249 1. 0 1. 6 13. 7 (11. 7-15. 7) 9. 7 (6. 0-13. 5) South Carolina 8, 485 1. 0 1. 6 10. 1 (8. 7-11. 6) 8. 1 (4. 8-11. 5) South Dakota 5, 511 1. 0 1. 5 8. 8 (7. 2-10. 5) 5. 9 (2. 69. 3) Tennessee 4, 115 1. 0 1. 6 11. 1 (9. 2-13. 1) 9. 6 (5. 6-13. 6) Texas 10, 433 1. 0 1. 7 12. 1 (10. 4-13. 8) 10. 9 (6. 6-15. 1) Utah 8, 737 1. 0 1. 7 12. 5 (10. 9-14. 1) 9. 4 (5. 1-13. 7) Vermont 4, 877 1. 1 1. 8 12. 7 (10. 9-14. 5) 11. 1 (7. 5-14. 6) Virginia 6, 593 1. 0 1. 6 10. 9 (9. 3-12. 5) 7. 6 (3. 9-11. 4) Washington 12, 247 1. 0 1. 8 12. 6 (11. 1-14. 2) 10. 9 (7. 1-14. 8) West Virginia 4, 200 1. 0 1. 5 7. 3 (6. 08. 7) 5. 8 (2. 78. 9) Wisconsin 4, 894 1. 0 1. 6 11. 7 (10. 0-13. 5) 7. 8 (4. 0-11. 5) Wyoming 3, 977 1. 0 1. 7 12. 1 (9. 9-14. 2) 9. 1 (4. 8-13. 5) Abbreviation: CI = confidence interval. intake (9. 2% and 6. 7%, respectively); this proportion was significantly different from the referent group of adults aged 51 years, 12. 4% and 10. 9% of whom met intake recom - mendations for fruit and vegetables, respectively. Findings varied by state; in 41 states, a significantly lower percentage of young adults met recommendations for vegetable intake than did older adults, whereas this pattern was only observed for fruit intake in 18 states. A significantly higher propor - tion of Hispanics and blacks met recommendations for fruit intake than did whites; however, these differences were only significant in 10 states (Table 2) . There were no significant differences in meeting recommendations for vegetable intake Morbidity and Mortality Weekly Report 1244 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and PreventionTABLE 2. State-specific percentages of respondents meeting federal fruit intake recommendations * by sex, age, race/ethnicity, and income-topoverty ratio (IPR)  Behavioral Risk Factor Surveillance System, United States, 2015 JurisdictionSex Age group (yrs) Race/Ethnicity IPR Male Female (Ref) 1830 3150 51 (Ref) Black Hispanic White (Ref) <1. 25 1. 253. 49 >3. 49 (Ref) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) National 9. 2 (5. 8-12. 7) 15. 1 (11. 8-18. 7) 9. 2 (7. 1-11. 4) 13. 8 (11. 9-15. 9) 12. 4 (11. 0-13. 8) 14. 3 (12. 5-16. 2) 15. 7 (13. 5-17. 8) 11. 2 (10. 1-12. 3) 11. 9 (10. 6-13. 6) 11. 3 (9. 9-12. 8) 13. 0 (11. 6-14. 3) Alabama 7. 5 (4. 0-11. 0) 10. 0 (6. 4-13. 5) 8. 4 (4. 8-12. 1) 9. 6 (6. 9-12. 3) 8. 3 (6. 6-10. 0) 11. 6 (8. 6-14. 6) 11. 1 (4. 6-17. 5) 7. 6 (6. 19. 1) 9. 1 (6. 4-11. 9) 7. 7 (5. 79. 7) 9. 5 (7. 5-11. 4) Alaska 10. 0 (4. 4-15. 7) 16. 1 (10. 4-21. 8) 9. 5 (4. 1-14. 9) 15. 4 (11. 0-19. 9) 12. 8 (9. 9-15. 7) 14. 6 (6. 5-22. 6) 12. 9 (10. 2-15. 5) 11. 1 (6. 1-16. 1) 11. 3 (8. 0-14. 6) 14. 4 (11. 1-17. 7) Arizona 10. 4 (5. 7-15. 0) 16. 2 (11. 5-20. 8) 10. 4 (5. 9-15. 0) 15. 9 (12. 4-19. 4) 12. 5 (10. 4-14. 7) 19. 2 (9. 3-29. 1) 15. 9 (11. 9-19. 8) 12. 1 (10. 1-14. 0) 13. 6 (10. 1-17. 1) 11. 0 (8. 4-13. 6) 15. 0 (12. 4-17. 6) Arkansas 7. 3 (2. 9-11. 7) 11. 7 (7. 3-16. 1) 9. 6 (3. 7-15. 6) 10. 4 (6. 9-13. 8) 8. 7 (6. 8-10. 7) 11. 5 (5. 4-17. 5) 16. 4 (7. 7-25. 1) 8. 6 (6. 6-10. 6) 10. 0 (6. 5-13. 5) 9. 1 (6. 1-12. 0) 9. 6 (6. 8-12. 4) California 10. 4 (6. 0-14. 8) 16. 8 (12. 4-21. 2) 9. 3 (6. 2-12. 5) 16. 0 (13. 1-18. 9) 13. 8 (11. 5-16. 0) 14. 1 (9. 6-18. 5) 15. 9 (13. 1-18. 7) 12. 4 (10. 6-14. 1) 13. 9 (11. 2-16. 6) 13. 0 (10. 5-15. 5) 13. 8 (11. 8-15. 8) Colorado 10. 2 (6. 0-14. 4) 17. 0 (12. 8-21. 1) 9. 4 (5. 4-13. 4) 16. 3 (12. 7-19. 8) 13. 2 (10. 9-15. 2) 18. 7 (10. 2-27. 1) 16. 5 (12. 4-20. 6) 12. 5 (10. 6-14. 4) 12. 2 (8. 9-15. 5) 12. 3 (9. 6-15. 1) 14. 6 (12. 3-17. 0) Connecticut 9. 7 (5. 9-13. 4) 17. 2 (13. 4-20. 9) 8. 6 (4. 7-12. 5) 14. 9 (11. 8-18. 1) 14. 4 (12. 3-16. 5) 16. 1 (11. 8-20. 4) 14. 7 (10. 6-18. 8) 13. 1 (11. 3-14. 9) 11. 7 (8. 9-14. 4) 13. 0 (10. 4-15. 5) 14. 2 (12. 1-16. 3) Delaware 8. 9 (5. 2-12. 7) 15. 9 (12. 1-19. 6) 7. 3 (2. 9-11. 7) 14. 3 (10. 3-18. 3) 13. 0 (10. 5-15. 6) 16. 9 (12. 0-21. 8) 14. 4 (8. 0-20. 7) 11. 1 (8. 9-13. 3) 9. 8 (6. 4-13. 3) 11. 0 (8. 1-14. 0) 14. 1 (11. 3-17. 0) District of Columbia13. 4 (8. 1-18. 8) 17. 5 (12. 2-22. 8) 9. 1 (2. 8-15. 5) 21. 2 (15. 4-26. 9) 13. 8 (11. 0-16. 5) 15. 9 (11. 4-20. 4) 25. 9 (13. 1-38. 7) 13. 5 (9. 7-17. 3) 19. 4 (12. 3-26. 5) 14. 7 (8. 3-21. 2) 14. 8 (11. 2-18. 3) Florida 11. 2 (7. 4-14. 9) 16. 8 (13. 0-20. 5) 13. 9 (8. 6-19. 2) 15. 9 (12. 6-19. 2) 12. 9 (10. 9-14. 8) 16. 9 (12. 4-21. 4) 16. 6 (12. 5-20. 7) 12. 2 (10. 3-14. 1) 13. 2 (10. 2-16. 1) 13. 6 (10. 7-16. 5) 14. 7 (12. 4-17. 1) Georgia 8. 9 (4. 8-12. 9) 14. 8 (10. 7-18. 9) 9. 1 (4. 7-13. 5) 14. 4 (10. 7-18. 2) 11. 2 (9. 0-13. 4) 12. 5 (9. 3-15. 7) 18. 1 (9. 8-26. 3) 10. 8 (8. 7-13. 0) 11. 2 (7. 6-14. 8) 11. 8 (8. 8-14. 8) 12. 5 (10. 0-15. 1) Hawaii 9. 8 (5. 5-14. 1) 14. 9 (10. 7-19. 2) 9. 9 (5. 4-14. 4) 12. 5 (9. 4-15. 7) 13. 3 (11. 2-15. 5) 15. 4 (10. 2-20. 5) 14. 8 (11. 8-17. 8) 12. 7 (9. 4-16. 1) 11. 7 (9. 0-14. 5) 12. 6 (10. 4-14. 8) Idaho 8. 4 (4. 4-12. 4) 15. 1 (11. 1-19. 1) 8. 3 (4. 3-12. 3) 13. 2 (9. 5-16. 9) 12. 1 (9. 9-14. 3) 12. 9 (7. 8-18. 0) 11. 7 (9. 7-13. 6) 11. 3 (7. 7-15. 0) 10. 9 (8. 3-13. 5) 12. 8 (10. 4-15. 2) Illinois 11. 1 (6. 8-15. 3) 16. 9 (12. 6-21. 1) 10. 7 (6. 4-15. 0) 15. 8 (12. 1-19. 5) 14. 4 (12. 1-16. 7) 14. 7 (10. 2-19. 2) 19. 8 (14. 2-25. 3) 12. 8 (10. 8-14. 7) 13. 3 (9. 6-17. 0) 13. 1 (10. 3-16. 0) 14. 9 (12. 4-17. 3) Indiana 8. 8 (4. 5-13. 1) 14. 1 (9. 8-18. 4) 9. 9 (5. 2-14. 7) 13. 2 (9. 4-17. 0) 11. 0 (8. 9-13. 1) 13. 3 (7. 6-19. 0) 18. 2 (9. 5-26. 9) 10. 9 (8. 9-12. 9) 12. 0 (7. 6-16. 4) 9. 8 (7. 3-12. 3) 12. 7 (10. 0-15. 4) Iowa 7. 0 (3. 3-10. 8) 14. 3 (10. 6-18. 1) 7. 3 (3. 2-11. 3) 11. 1 (7. 8-14. 4) 11. 9 (9. 8-14. 0) 7. 9 (2. 6-13. 2) 15. 6 (6. 9-24. 4) 10. 4 (8. 7-12. 1) 9. 4 (6. 2-12. 6) 10. 0 (7. 4-12. 7) 11. 4 (9. 3-13. 6) Kansas 6. 7 (3. 1-10. 3) 13. 2 (9. 6-16. 8) 6. 4 (4. 18. 8) 11. 1 (8. 7-13. 4) 10. 8 (9. 2-12. 4) 12. 0 (8. 2-15. 7) 12. 6 (9. 5-15. 6) 9. 6 (8. 3-10. 9) 8. 7 (6. 7-10. 7) 9. 2 (7. 5-10. 9) 11. 0 (9. 5-12. 6) Kentucky 5. 7 (1. 59. 9) 10. 5 (6. 4-14. 7) 5. 5 (2. 38. 7) 8. 2 (5. 5-10. 8) 9. 2 (7. 1-11. 3) 8. 5 (4. 7-12. 4) 5. 5 (1. 79. 3) 8. 1 (6. 59. 7) 6. 9 (4. 79. 1) 7. 2 (4. 89. 5) 9. 3 (7. 3-11. 4) Louisiana 9. 9 (5. 9-13. 9) 12. 4 (8. 4-16. 4) 8. 7 (4. 7-12. 7) 13. 6 (9. 9-17. 3) 10. 4 (8. 2-12. 5) 13. 7 (10. 3-17. 1) 14. 5 (6. 1-23. 0) 10. 0 (7. 8-12. 1) 11. 4 (8. 0-14. 7) 10. 7 (7. 8-13. 6) 11. 5 (8. 8-14. 1) Maine 9. 7 (6. 1-13. 2) 18. 4 (14. 8-22. 0) 11. 5 (6. 6-16. 4) 14. 7 (10. 7-18. 7) 14. 7 (12. 5-16. 9) 20. 0 (7. 6-32. 3) 14. 1 (12. 2-16. 1) 10. 7 (7. 6-13. 7) 13. 9 (11. 0-16. 8) 15. 5 (13. 1-18. 0) Maryland 10. 9 (6. 9-14. 8) 16. 8 (12. 8-20. 7) 10. 6 (5. 5-15. 6) 15. 2 (11. 4-19. 1) 14. 5 (12. 0-17. 0) 18. 0 (13. 7-22. 2) 13. 6 (7. 1-20. 1) 12. 2 (10. 2-14. 3) 14. 4 (9. 4-19. 4) 13. 8 (10. 3-17. 3) 14. 0 (11. 6-16. 4) Massachusetts 10. 3 (6. 4-14. 3) 17. 4 (13. 4-21. 3) 8. 8 (5. 4-12. 1) 15. 8 (12. 4-19. 2) 14. 9 (12. 6-17. 3) 18. 3 (12. 3-24. 3) 17. 8 (12. 9-22. 6) 13. 5 (11. 6-15. 4) 12. 5 (9. 3-15. 6) 13. 3 (10. 5-16. 1) 14. 6 (12. 4-16. 8) Michigan 8. 3 (4. 6-11. 9) 15. 5 (11. 9-19. 2) 9. 0 (5. 3-12. 6) 12. 8 (9. 7-15. 9) 12. 5 (10. 4-14. 5) 14. 8 (11. 0-18. 6) 16. 1 (10. 1-22. 1) 11. 4 (9. 7-13. 1) 11. 7 (8. 6-14. 9) 10. 4 (8. 2-12. 6) 13. 1 (11. 0-15. 2) Minnesota 7. 7 (4. 2-11. 2) 15. 6 (12. 1-19. 1) 7. 8 (4. 9-10. 7) 12. 4 (9. 6-15. 1) 12. 8 (10. 9-14. 7) 13. 1 (8. 8-17. 4) 14. 7 (9. 6-19. 8) 11. 6 (10. 1-13. 1) 9. 5 (7. 0-12. 1) 10. 1 (8. 1-12. 0) 13. 0 (11. 2-14. 8) Mississippi 7. 1 (3. 3-10. 8) 10. 3 (6. 5-14. 1) 9. 5 (5. 3-13. 7) 9. 5 (6. 7-12. 4) 7. 7 (5. 99. 4) 10. 0 (7. 2-12. 8)  7. 8 (6. 19. 6) 8. 5 (5. 9-11. 1) 7. 8 (5. 5-10. 2) 10. 1 (7. 7-12. 5) Missouri 7. 9 (3. 9-12. 0) 13. 6 (9. 6-17. 7) 8. 2 (4. 3-12. 1) 11. 3 (8. 1-14. 5) 11. 6 (9. 5-13. 6) 15. 1 (10. 4-19. 9) 11. 9 (3. 7-20. 2) 10. 1 (8. 4-11. 8) 9. 4 (6. 3-12. 5) 10. 1 (7. 7-12. 4) 11. 8 (9. 6-14. 1) Montana 7. 3 (3. 3-11. 3) 14. 1 (10. 1-18. 1) 8. 1 (3. 6-12. 5) 11. 2 (7. 6-14. 8) 11. 3 (9. 1-13. 5) 14. 3 (5. 8-22. 8) 10. 5 (8. 6-12. 4) 9. 5 (6. 3-12. 7) 10. 2 (7. 4-13. 0) 11. 5 (9. 2-13. 8) Nebraska 8. 4 (4. 5-12. 3) 14. 4 (10. 5-18. 3) 8. 1 (4. 9-11. 3) 12. 0 (9. 1-14. 9) 12. 5 (10. 6-14. 5) 17. 4 (10. 7-24. 2) 17. 4 (12. 2-22. 5) 10. 5 (9. 0-12. 0) 10. 7 (8. 0-13. 3) 11. 2 (9. 0-13. 5) 11. 7 (9. 9-13. 6) Nevada 11. 2 (6. 6-15. 9) 15. 0 (10. 4-19. 7) 13. 6 (6. 3-20. 9) 13. 8 (9. 4-18. 1) 12. 2 (9. 1-15. 2) 18. 2 (8. 4-28. 0) 11. 5 (7. 1-15. 9) 12. 8 (9. 8-15. 9) 18. 3 (11. 2-25. 3) 10. 3 (7. 1-13. 6) 13. 1 (9. 7-16. 5) New Hampshire10. 8 (7. 0-14. 6) 17. 8 (14. 0-21. 6) 11. 5 (5. 2-17. 7) 14. 9 (10. 9-18. 9) 14. 9 (12. 5-17. 3) 14. 6 (12. 4-16. 8) 13. 2 (8. 6-17. 8) 11. 6 (8. 7-14. 5) 16. 1 (13. 4-18. 7) New Jersey 9. 5 (5. 7-13. 2) 14. 7 (10. 9-18. 5) 8. 4 (4. 6-12. 1) 12. 8 (9. 9-15. 7) 13. 2 (10. 9-15. 5) 15. 1 (11. 2-19. 1) 12. 3 (9. 0-15. 7) 11. 3 (9. 5-13. 2) 10. 8 (7. 7-13. 9) 12. 0 (9. 4-14. 6) 12. 6 (10. 5-14. 7) New Mexico 8. 8 (4. 4-13. 2) 15. 6 (11. 2-20. 0) 8. 0 (4. 5-11. 5) 15. 6 (12. 0-19. 1) 11. 8 (9. 5-14. 1) 25. 8 (12. 3-39. 3) 12. 8 (10. 0-15. 6) 10. 4 (8. 5-12. 3) 13. 2 (10. 2-16. 2) 10. 2 (7. 9-12. 6) 13. 4 (10. 8-16. 1) New York 10. 6 (6. 7-14. 4) 17. 2 (13. 3-21. 1) 9. 4 (6. 2-12. 6) 15. 8 (12. 7-18. 9) 14. 8 (12. 7-16. 8) 17. 0 (13. 1-21. 0) 17. 0 (13. 4-20. 6) 13. 3 (11. 5-15. 0) 13. 8 (11. 0-16. 5) 13. 3 (11. 0-15. 7) 14. 5 (12. 4-16. 6) North Carolina 7. 8 (4. 1-11. 5) 12. 9 (9. 2-16. 7) 7. 7 (4. 4-11. 0) 12. 5 (9. 6-15. 4) 9. 8 (7. 9-11. 8) 13. 4 (10. 1-16. 8) 16. 4 (11. 2-21. 5) 8. 9 (7. 3-10. 5) 10. 1 (7. 3-12. 8) 9. 9 (7. 5-12. 3) 11. 0 (9. 0-12. 9) North Dakota 8. 3 (3. 8-12. 7) 15. 7 (11. 3-20. 1) 7. 1 (3. 2-10. 9) 12. 5 (8. 9-16. 2) 14. 0 (11. 6-16. 4)  11. 1 (9. 3-12. 9) 9. 2 (5. 7-12. 8) 11. 6 (8. 5-14. 6) 12. 6 (10. 3-14. 8) Ohio 7. 5 (3. 7-11. 3) 13. 7 (9. 9-17. 6) 9. 1 (5. 0-13. 2) 10. 8 (7. 8-13. 8) 11. 1 (9. 2-13. 0) 13. 1 (8. 3-17. 9) 20. 5 (9. 8-31. 2) 9. 8 (8. 2-11. 4) 10. 8 (7. 4-14. 1) 9. 2 (7. 0-11. 4) 11. 6 (9. 5-13. 8) Oklahoma 5. 6 (1. 99. 3) 10. 3 (6. 6-14. 0) 4. 8 (1. 87. 8) 9. 5 (6. 5-12. 4) 8. 3 (6. 6-10. 0) 11. 1 (5. 9-16. 2) 11. 4 (6. 4-16. 3) 7. 4 (5. 98. 9) 6. 7 (4. 19. 3) 8. 2 (6. 0-10. 4) 8. 5 (6. 7-10. 3) Oregon 9. 6 (5. 6-13. 7) 17. 0 (13. 0-21. 1) 8. 6 (4. 2-12. 9) 14. 6 (10. 7-18. 4) 14. 5 (12. 0-17. 0) 16. 1 (9. 4-22. 8) 13. 2 (11. 1-15. 2) 11. 0 (7. 1-15. 0) 12. 8 (9. 9-15. 8) 14. 6 (12. 1-17. 1) Pennsylvania 8. 6 (4. 6-12. 6) 14. 7 (10. 8-18. 7) 8. 3 (4. 4-12. 3) 12. 8 (9. 2-16. 4) 12. 4 (10. 2-14. 6) 15. 7 (10. 8-20. 6) 14. 1 (6. 6-21. 6) 11. 2 (9. 3-13. 0) 11. 8 (7. 1-16. 5) 10. 3 (7. 9-12. 7) 12. 7 (10. 5-14. 9) Rhode Island 10. 4 (6. 5-14. 4) 16. 8 (12. 9-20. 7) 11. 8 (6. 3-17. 3) 13. 5 (9. 9-17. 1) 14. 6 (12. 2-17. 1) 14. 5 (6. 8-22. 3) 17. 5 (11. 1-24. 0) 12. 8 (10. 8-14. 8) 14. 8 (10. 5-19. 1) 11. 9 (8. 9-15. 0) 14. 5 (11. 9-17. 1) South Carolina 7. 6 (4. 0-11. 2) 12. 5 (8. 9-16. 1) 7. 9 (4. 7-11. 1) 12. 2 (9. 4-14. 9) 9. 6 (7. 9-11. 4) 11. 4 (8. 9-13. 8) 24. 4 (15. 6-33. 2) 8. 7 (7. 3-10. 2) 10. 9 (8. 2-13. 7) 9. 8 (7. 7-11. 8) 10. 1 (8. 3-11. 9) South Dakota 5. 9 (2. 39. 6) 11. 9 (8. 3-15. 5) 5. 9 (2. 29. 7) 9. 9 (6. 7-13. 2) 9. 2 (7. 3-11. 2) 13. 5 (2. 0-24. 9) 8. 8 (7. 1-10. 5) 8. 2 (4. 6-11. 8) 8. 3 (6. 0-10. 7) 9. 4 (7. 4-11. 5) Tennessee 8. 4 (4. 2-12. 6) 13. 9 (9. 7-18. 1) 9. 5 (4. 8-14. 1) 12. 9 (9. 1-16. 8) 10. 5 (8. 4-12. 5) 14. 4 (9. 0-19. 7) 16. 4 (4. 8-28. 0) 10. 3 (8. 4-12. 3) 10. 1 (6. 5-13. 8) 10. 5 (7. 7-13. 3) 12. 4 (9. 7-15. 0) Texas 9. 3 (4. 9-13. 8) 14. 9 (10. 4-19. 3) 8. 4 (4. 8-12. 1) 14. 8 (11. 7-17. 9) 11. 6 (9. 4-13. 8) 13. 1 (8. 7-17. 5) 14. 2 (11. 1-17. 3) 10. 4 (8. 5-12. 2) 12. 9 (9. 8-16. 0) 11. 6 (9. 0-14. 3) 12. 1 (9. 8-14. 3) Utah 9. 1 (4. 5-13. 7) 15. 9 (11. 3-20. 5) 8. 0 (5. 0-11. 0) 14. 3 (11. 3-17. 4) 13. 8 (11. 6-16. 0) 15. 7 (11. 7-19. 7) 12. 2 (10. 4-13. 9) 10. 8 (7. 8-13. 9) 11. 7 (9. 2-14. 2) 13. 5 (11. 5-15. 5) Vermont 8. 7 (5. 0-12. 4) 16. 7 (13. 0-20. 4) 8. 1 (4. 0-12. 3) 12. 5 (9. 1-15. 9) 14. 6 (12. 3-17. 0)  12. 7 (10. 9-14. 6) 9. 2 (6. 6-11. 9) 10. 9 (8. 4-13. 5) 14. 9 (12. 5-17. 3) Virginia 8. 5 (4. 5-12. 5) 13. 2 (9. 2-17. 2) 9. 7 (6. 0-13. 3) 11. 6 (8. 8-14. 4) 10. 9 (8. 9-13. 0) 13. 0 (9. 7-16. 3) 14. 2 (8. 9-19. 5) 9. 8 (8. 2-11. 5) 10. 3 (7. 1-13. 5) 10. 1 (7. 7-12. 5) 11. 5 (9. 6-13. 5) Washington 9. 2 (5. 1-13. 2) 16. 1 (12. 0-20. 1) 8. 9 (5. 7-12. 1) 13. 9 (10. 9-16. 9) 13. 4 (11. 4-15. 4) 17. 1 (10. 6-23. 6) 16. 2 (12. 0-20. 4) 12. 0 (10. 4-13. 6) 13. 9 (10. 7-17. 1) 11. 6 (9. 3-14. 0) 12. 9 (11. 1-14. 7) West Virginia 5. 2 (1. 88. 5) 9. 5 (6. 2-12. 9) 6. 1 (2. 89. 3) 7. 4 (4. 9-10. 0) 7. 8 (6. 19. 5) 9. 4 (3. 7-15. 2)  7. 2 (5. 88. 6) 5. 8 (3. 87. 9) 6. 5 (4. 78. 3) 9. 2 (7. 2-11. 2) Wisconsin 8. 0 (4. 0-11. 9) 15. 6 (11. 6-19. 6) 8. 2 (4. 4-12. 0) 12. 4 (9. 1-15. 7) 12. 9 (10. 6-15. 2) 17. 9 (9. 7-26. 1) 15. 6 (8. 5-22. 6) 11. 2 (9. 5-13. 0) 12. 2 (8. 4-16. 0) 10. 4 (8. 0-12. 7) 12. 7 (10. 4-15. 0) Wyoming 9. 0 (4. 5-13. 6) 15. 3 (11. 8-18. 7) 10. 7 (5. 1-16. 4) 13. 9 (10. 0-17. 9) 11. 4 (11. 0-13. 8) 17. 4 (9. 2-25. 6) 10. 6 (8. 7-12. 6) 13. 6 (7. 3-19. 9) 11. 0 (7. 8-14. 2) 12. 6 (10. 0-15. 1) Abbreviations: CI = confidence interval; Ref = referent group. * W eighted percentages are presented.  Blacks and whit es are non-Hispanic; Hispanic persons could be of any race. Other racial/ethnic group not reported because of small sample sizes but included in overall estimates and estimates by other demographic characteristics.  Da ta where the sample sizes were <50 were considered unstable and were not reported.  p<0. 05 f or t-test comparing differences by demographic groups to the referent group. Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1245 US Department of Health and Human Services/Centers for Disease Control and PreventionTABLE 3. State-specific percentages * of respondents meeting federal vegetable intake recommendations sex, age, race/ethnicity, and incometo-poverty ratio (IPR)  Behavioral Risk Factor Surveillance System, 2015 StateSex (n = 319, 415) Age group (yrs, n = 319, 415) Race/Ethnicity IPR (n = 319, 415) Men Women (Ref) 1830 3150 51 (Ref) Black Hispanic White (Ref) <1. 25 1. 253. 49 >3. 49 (Ref) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) National 7. 6 (5. 69. 6) 10. 9 (9. 0-13. 0) 6. 7 (4. 78. 7) 8. 8 (6. 9-10. 9) 10. 9 (8. 9-12. 9) 5. 5 (0. 0-11. 1) 10. 5 (5. 0-16. 1) 9. 5 (3. 9-15. 1) 7. 0 (3. 9-10. 4) 7. 5 (4. 3-10. 8) 11. 4 (8. 2-14. 7) Alabama 5. 4 (3. 37. 5) 6. 7 (4. 68. 8) 3. 0 (0. 75. 3) 5. 3 (3. 07. 7) 8. 0 (5. 7-10. 3) 3. 1 (0. 0-11. 3) 7. 0 (0. 0-15. 2) 3. 4 (0. 07. 2) 4. 9 (1. 28. 7) 8. 4 (4. 6-12. 1) Alaska 8. 9 (4. 2-13. 5) 15. 6 (10. 9-20. 2) 9. 9 (6. 1-13. 7) 11. 7 (7. 9-15. 5) 13. 7 (9. 8-17. 5) 13. 2 (4. 3-22. 1) 12. 9 (4. 0-21. 8) 11. 7 (6. 1-17. 3) 9. 4 (3. 8-15. 0) 13. 9 (8. 3-19. 5) Arizona 8. 0 (4. 7-11. 2) 13. 0 (9. 8-16. 3) 7. 7 (4. 8-10. 5) 10. 6 (7. 7-13. 4) 11. 8 (9. 0-14. 7) 5. 2 (0. 0-14. 9) 11. 4 (1. 7-21. 1) 10. 4 (0. 7-20. 1) 10. 1 (5. 8-14. 4) 8. 1 (3. 8-12. 3) 12. 8 (8. 5-17. 0) Arkansas 6. 9 (4. 29. 6) 8. 8 (6. 1-11. 5) 5. 9 (3. 18. 8) 6. 6 (3. 89. 5) 9. 8 (6. 9-12. 6) 9. 9 (3. 0-16. 8) 8. 4 (1. 5-15. 3) 6. 3 (1. 1-11. 5) 6. 6 (1. 4-11. 8) 10. 2 (5. 0-15. 5) California 9. 3 (6. 3-12. 3) 13. 0 (10. 1-16. 0) 7. 5 (4. 4-10. 5) 11. 2 (8. 2-14. 2) 13. 3 (10. 2-16. 3) 6. 6 (0. 3-13. 0) 10. 6 (4. 3-17. 0) 11. 8 (5. 5-18. 2) 9. 3 (5. 1-13. 5) 9. 1 (4. 9-13. 4) 13. 1 (8. 9-17. 3) Colorado 8. 6 (5. 3-11. 8) 14. 6 (11. 4-17. 9) 8. 8 (5. 9-11. 8) 11. 0 (8. 0-13. 9) 13. 5 (10. 5-16. 4) 8. 6 (0. 2-17. 1) 11. 9 (3. 5-20. 3) 11. 5 (3. 1-20. 0) 9. 4 (5. 3-13. 4) 10. 0 (6. 0-14. 1) 13. 1 (9. 1-17. 2) Connecticut 7. 8 (4. 7-10. 8) 12. 9 (9. 8-15. 9) 9. 5 (6. 9-12. 1) 9. 3 (6. 7-11. 9) 11. 5 (8. 9-14. 1) 5. 2 (0. 0-13. 8) 8. 7 (0. 2-17. 3) 11. 1 (2. 6-19. 7) 7. 9 (4. 0-11. 8) 8. 1 (4. 2-12. 0) 12. 1 (8. 2-16. 0) Delaware 6. 4 (3. 09. 7) 10. 6 (7. 3-14. 0) 5. 7 (2. 68. 7) 7. 5 (4. 5-10. 6) 10. 4 (7. 4-13. 4) 6. 3 (0. 0-16. 3) 5. 6 (0. 0-15. 6) 9. 1 (0. 0-19. 1) 4. 6 (0. 68. 5) 6. 2 (2. 2-10. 1) 11. 1 (7. 1-15. 1) District of Columbia8. 4 (3. 9-12. 9) 10. 9 (6. 4-15. 4) 5. 0 (1. 68. 3) 10. 9 (7. 5-14. 3) 12. 0 (8. 6-15. 3) 6. 3 (0. 0-17. 0) 14. 2 (3. 4-24. 9) 11. 6 (0. 8-22. 3) 6. 2 (0. 3-12. 1) 7. 1 (1. 2-13. 0) 11. 5 (5. 6-17. 5) Florida 8. 2 (5. 4-11. 1) 12. 2 (9. 4-15. 1) 9. 5 (7. 0-12. 0) 9. 3 (6. 8-11. 8) 11. 2 (8. 7-13. 7) 6. 7 (0. 0-16. 1) 8. 7 (0. 0-18. 1) 11. 1 (1. 7-20. 5) 7. 9 (3. 7-12. 1) 7. 3 (3. 2-11. 5) 13. 6 (9. 4-17. 8) Georgia 6. 4 (3. 59. 3) 10. 5 (7. 6-13. 4) 6. 8 (4. 19. 5) 8. 1 (5. 4-10. 8) 9. 8 (7. 1-12. 4) 5. 4 (0. 0-15. 2) 7. 1 (0. 0-16. 9) 10. 1 (0. 3-19. 9) 4. 5 (0. 18. 9) 7. 6 (3. 3-12. 0) 11. 2 (6. 8-15. 6) Hawaii 9. 7 (6. 4-12. 9) 13. 5 (10. 2-16. 7) 7. 9 (4. 7-11. 0) 10. 2 (7. 0-13. 4) 14. 2 (11. 0-17. 4) 9. 4 (4. 6-14. 3) 13. 3 (8. 5-18. 2) 8. 5 (4. 5-12. 5) 10. 8 (6. 8-14. 7) 12. 8 (8. 9-16. 8) Idaho 8. 7 (5. 3-12. 1) 12. 9 (9. 5-16. 2) 8. 4 (5. 5-11. 3) 11. 4 (8. 4-14. 3) 11. 4 (8. 5-14. 3) 12. 5 (3. 7-21. 3) 10. 5 (1. 7-19. 3) 7. 7 (3. 8-11. 7) 9. 6 (5. 7-13. 6) 13. 3 (9. 3-17. 2) Illinois 8. 0 (5. 2-10. 9) 11. 3 (8. 5-14. 1) 7. 5 (4. 8-10. 1) 9. 0 (6. 3-11. 7) 11. 5 (8. 8-14. 2) 6. 1 (0. 0-18. 6) 14. 1 (1. 6-26. 6) 9. 4 (0. 0-21. 9) 9. 6 (5. 6-13. 7) 7. 9 (3. 9-12. 0) 10. 9 (6. 9-15. 0) Indiana 7. 6 (4. 9-10. 3) 9. 5 (6. 8-12. 2) 4. 0 (1. 46. 6) 9. 7 (7. 1-12. 3) 10. 1 (7. 5-12. 7) 9. 6 (0. 0-22. 1) 8. 9 (0. 0-21. 4) 4. 4 (0. 09. 5) 7. 2 (2. 1-12. 2) 11. 5 (6. 5-16. 5) Iowa 5. 3 (2. 77. 9) 8. 8 (6. 2-11. 3) 4. 7 (2. 27. 1) 5. 8 (3. 38. 2) 9. 1 (6. 7-11. 6) 11. 7 (1. 4-22. 0) 6. 9 (0. 0-17. 2) 6. 2 (2. 3-10. 1) 5. 9 (2. 09. 8) 8. 1 (4. 2-12. 0) Kansas 6. 5 (4. 38. 7) 9. 8 (7. 5-12. 0) 4. 5 (2. 36. 8) 7. 6 (5. 39. 8) 10. 3 (8. 0-12. 5) 4. 6 (0. 0-10. 4) 9. 1 (3. 4-14. 9) 8. 1 (2. 4-13. 9) 5. 8 (2. 59. 1) 6. 4 (3. 29. 7) 10. 2 (6. 9-13. 4) Kentucky 5. 1 (2. 47. 8) 7. 6 (4. 9-10. 3) 3. 6 (0. 96. 4) 5. 1 (2. 47. 8) 8. 6 (5. 8-11. 3) 6. 5 (0. 0-16. 3) 4. 8 (0. 29. 4) 4. 1 (0. 08. 7) 8. 8 (4. 2-13. 3) Louisiana 8. 0 (5. 4-10. 7) 8. 6 (5. 9-11. 2) 6. 6 (4. 19. 1) 8. 5 (6. 0-11. 0) 9. 0 (6. 5-11. 5) 5. 0 (0. 0-13. 9) 7. 7 (0. 0-16. 6) 10. 0 (1. 1-18. 9) 4. 5 (0. 09. 0) 9. 0 (4. 4-13. 6) 9. 9 (5. 3-14. 5) Maine 7. 7 (4. 7-10. 8) 13. 6 (10. 5-16. 6) 9. 8 (7. 1-12. 5) 8. 6 (5. 9-11. 3) 12. 4 (9. 7-15. 0) 10. 7 (0. 0-21. 5) 7. 1 (3. 4-10. 8) 9. 0 (5. 3-12. 7) 13. 5 (9. 8-17. 2) Maryland 6. 9 (3. 8-10. 0) 10. 9 (7. 8-14. 0) 5. 8 (2. 98. 7) 8. 0 (5. 1-10. 9) 11. 3 (8. 4-14. 2) 5. 4 (0. 0-14. 6) 11. 2 (1. 9-20. 4) 9. 6 (0. 4-18. 9) 5. 9 (2. 49. 5) 6. 8 (3. 2-10. 4) 11. 0 (7. 4-14. 6) Massachusetts 8. 7 (5. 7-11. 8) 13. 3 (10. 2-16. 3) 8. 3 (5. 3-11. 3) 10. 8 (7. 8-13. 8) 12. 6 (9. 6-15. 6) 5. 6 (0. 0-13. 7) 11. 4 (3. 3-19. 5) 11. 2 (3. 1-19. 3) 8. 1 (4. 0-12. 1) 8. 9 (4. 9-13. 0) 12. 7 (8. 7-16. 8) Michigan 5. 6 (3. 18. 1) 9. 8 (7. 3-12. 3) 4. 4 (1. 96. 9) 6. 8 (4. 39. 3) 9. 7 (7. 2-12. 2) 5. 5 (0. 0-13. 4) 7. 9 (0. 0-15. 8) 8. 0 (0. 1-15. 9) 5. 5 (1. 89. 3) 5. 7 (2. 09. 5) 9. 9 (6. 1-13. 7) Minnesota 6. 1 (3. 68. 6) 10. 2 (7. 7-12. 6) 5. 6 (3. 37. 9) 7. 7 (5. 4-10. 0) 9. 7 (7. 4-12. 0) 4. 3 (0. 0-12. 5) 12. 3 (4. 1-20. 5) 8. 1 (0. 0-16. 2) 5. 6 (2. 29. 0) 5. 9 (2. 59. 3) 10. 0 (6. 6-13. 4) Mississippi 5. 3 (2. 97. 7) 7. 0 (4. 69. 4) 5. 8 (3. 58. 0) 4. 6 (2. 46. 9) 7. 7 (5. 59. 9) 3. 1 (0. 0-23. 0) 7. 4 (0. 0-27. 3) 3. 7 (0. 08. 6) 4. 5 (0. 09. 3) 10. 2 (5. 4-15. 1) Missouri 6. 0 (3. 38. 6) 9. 4 (6. 7-12. 0) 5. 8 (3. 48. 3) 6. 6 (4. 29. 1) 9. 4 (6. 9-11. 8) 5. 2 (0. 0-12. 0) 5. 1 (0. 0-12. 0) 8. 0 (1. 2-14. 8) 3. 9 (0. 08. 0) 6. 8 (2. 7-10. 8) 9. 8 (5. 7-13. 9) Montana 5. 6 (2. 48. 8) 11. 0 (7. 8-14. 3) 5. 6 (2. 98. 3) 7. 5 (4. 9-10. 2) 9. 8 (7. 1-12. 5) 7. 9 (1. 1-14. 6) 8. 3 (1. 5-15. 0) 5. 3 (1. 49. 1) 7. 2 (3. 3-11. 0) 10. 3 (6. 5-14. 2) Nebraska 6. 8 (4. 49. 1) 9. 0 (6. 7-11. 4) 5. 3 (2. 97. 6) 7. 4 (5. 09. 7) 9. 6 (7. 2-11. 9) 6. 3 (0. 0-14. 5) 11. 8 (3. 5-20. 0) 7. 7 (0. 0-16. 0) 6. 7 (2. 7-10. 6) 6. 3 (2. 3-10. 3) 9. 5 (5. 5-13. 5) Nevada 9. 8 (5. 5-14. 0) 13. 3 (9. 0-17. 5) 14. 3 (10. 3-18. 3) 9. 2 (5. 2-13. 2) 12. 4 (8. 4-16. 3) 13. 6 (6. 2-21. 0) 11. 7 (4. 3-19. 1) 8. 9 (3. 4-14. 3) 9. 0 (3. 5-14. 4) 14. 5 (9. 0-19. 9) New Hampshire8. 5 (5. 2-11. 8) 13. 1 (9. 8-16. 4) 5. 5 (2. 68. 4) 11. 2 (8. 3-14. 1) 12. 4 (9. 5-15. 3) 10. 9 (3. 2-18. 6) 5. 9 (1. 8-10. 0) 9. 6 (5. 5-13. 7) 12. 3 (8. 2-16. 5) New Jersey 6. 2 (3. 29. 1) 10. 3 (7. 3-13. 2) 5. 4 (2. 48. 3) 6. 8 (3. 89. 7) 10. 6 (7. 7-13. 5) 4. 8 (0. 0-12. 7) 8. 8 (0. 9-16. 8) 8. 4 (0. 4-16. 3) 6. 8 (3. 0-10. 5) 5. 9 (2. 19. 7) 10. 1 (6. 3-13. 9) New Mexico 9. 1 (6. 0-12. 2) 11. 5 (8. 4-14. 6) 9. 1 (6. 1-12. 1) 9. 0 (6. 0-12. 0) 11. 9 (8. 9-14. 8) 10. 7 (2. 9-18. 4) 10. 1 (2. 3-17. 8) 8. 9 (4. 0-13. 8) 8. 7 (3. 8-13. 6) 12. 9 (8. 0-17. 8) New York 7. 7 (5. 0-10. 4) 11. 4 (8. 6-14. 1) 6. 9 (4. 49. 4) 9. 5 (7. 1-12. 0) 10. 9 (8. 4-13. 4) 7. 0 (0. 8-13. 2) 9. 8 (3. 7-16. 0) 10. 2 (4. 0-16. 4) 7. 1 (3. 2-11. 0) 7. 9 (4. 0-11. 8) 11. 7 (7. 8-15. 6) North Carolina 7. 3 (4. 89. 8) 8. 9 (6. 4-11. 4) 4. 4 (1. 77. 1) 7. 6 (4. 9-10. 3) 10. 3 (7. 6-13. 0) 3. 9 (0. 0-12. 4) 9. 7 (1. 1-18. 3) 8. 8 (0. 3-17. 4) 5. 3 (1. 49. 2) 6. 6 (2. 7-10. 5) 10. 5 (6. 6-14. 4) North Dakota 6. 4 (3. 59. 3) 9. 5 (6. 6-12. 4) 5. 6 (3. 08. 2) 7. 4 (4. 8-10. 0) 9. 6 (7. 0-12. 2)  7. 7 (0. 0-17. 4) 5. 0 (0. 89. 2) 6. 5 (2. 3-10. 8) 9. 3 (5. 1-13. 6) Ohio 5. 2 (2. 67. 8) 8. 7 (6. 1-11. 3) 4. 8 (2. 47. 1) 5. 9 (3. 68. 2) 8. 7 (6. 4-11. 0) 4. 4 (0. 0-12. 2) 9. 1 (1. 3-16. 9) 7. 1 (0. 0-14. 9) 4. 0 (0. 08. 3) 5. 0 (0. 79. 2) 9. 5 (5. 3-13. 8) Oklahoma 5. 4 (3. 27. 6) 6. 8 (4. 68. 9) 3. 0 (0. 75. 2) 5. 9 (3. 68. 1) 7. 7 (5. 5-10. 0) 2. 3 (0. 08. 0) 5. 5 (0. 0-11. 2) 6. 5 (0. 8-12. 1) 3. 2 (0. 07. 3) 5. 2 (1. 19. 2) 8. 3 (4. 3-12. 3) Oregon 10. 0 (6. 5-13. 5) 13. 8 (10. 3-17. 3) 10. 0 (6. 9-13. 0) 11. 8 (8. 7-14. 9) 12. 8 (9. 7-15. 9) 13. 6 (4. 0-23. 3) 12. 0 (2. 4-21. 6) 8. 3 (3. 8-12. 7) 10. 6 (6. 2-15. 1) 14. 1 (9. 6-18. 5) Pennsylvania 6. 9 (4. 09. 8) 9. 8 (6. 9-12. 7) 3. 7 (1. 06. 5) 8. 7 (5. 9-11. 4) 10. 1 (7. 3-12. 8) 6. 6 (0. 0-19. 5) 8. 5 (0. 0-21. 4) 6. 1 (1. 7-10. 5) 6. 8 (2. 4-11. 2) 10. 1 (5. 7-14. 5) Rhode Island 8. 2 (4. 8-11. 6) 11. 2 (7. 8-14. 6) 9. 6 (6. 7-12. 4) 8. 3 (5. 5-11. 1) 10. 9 (8. 1-13. 7) 10. 6 (0. 2-20. 9) 9. 7 (0. 0-20. 0) 7. 5 (3. 1-11. 8) 7. 5 (3. 2-11. 9) 12. 0 (7. 6-16. 3) South Carolina 6. 6 (4. 29. 1) 9. 5 (7. 1-12. 0) 6. 0 (3. 68. 3) 8. 0 (5. 7-10. 4) 9. 2 (6. 9-11. 6) 3. 1 (0. 0-11. 2) 20. 5 (12. 4-28. 6) 9. 0 (0. 9-17. 1) 5. 7 (1. 99. 5) 6. 1 (2. 39. 9) 11. 0 (7. 2-14. 8) South Dakota 4. 5 (2. 06. 9) 7. 5 (5. 0-10. 0) 2. 2 (0. 04. 6) 5. 4 (3. 07. 9) 7. 9 (5. 5-10. 3)  6. 3 (0. 6-11. 9) 3. 6 (0. 07. 2) 4. 9 (1. 38. 5) 7. 4 (3. 8-11. 0) Tennessee 9. 9 (6. 8-12. 9) 9. 4 (6. 4-12. 4) 9. 3 (6. 5-12. 1) 9. 2 (6. 4-12. 0) 10. 2 (7. 4-13. 0) 9. 7 (0. 0-25. 6) 10. 1 (0. 0-26. 0) 7. 6 (3. 0-12. 3) 7. 6 (3. 0-12. 3) 12. 7 (8. 1-17. 4) Texas 9. 7 (6. 6-12. 7) 12. 0 (9. 0-15. 1) 8. 0 (4. 9-11. 1) 10. 6 (7. 5-13. 7) 12. 7 (9. 6-15. 9) 7. 2 (0. 0-15. 6) 11. 7 (3. 2-20. 1) 11. 2 (2. 8-19. 6) 8. 8 (4. 1-13. 5) 10. 3 (5. 6-14. 9) 12. 4 (7. 7-17. 1) Utah 7. 8 (5. 1-10. 6) 11. 0 (8. 3-13. 8) 6. 6 (3. 89. 4) 9. 4 (6. 6-12. 2) 11. 6 (8. 8-14. 4) 11. 3 (0. 6-22. 1) 9. 3 (0. 0-20. 0) 7. 5 (3. 3-11. 7) 8. 4 (4. 2-12. 6) 10. 6 (6. 4-14. 9) Vermont 7. 7 (4. 3-11. 1) 14. 4 (11. 0-17. 8) 8. 4 (5. 4-11. 4) 9. 8 (6. 8-12. 7) 12. 9 (10. 0-15. 9)  11. 1 (2. 6-19. 6) 6. 5 (2. 4-10. 5) 7. 7 (3. 7-11. 8) 14. 6 (10. 5-18. 6) Virginia 6. 0 (3. 58. 6) 9. 2 (6. 6-11. 8) 5. 2 (2. 67. 8) 6. 7 (4. 19. 3) 9. 7 (7. 0-12. 3) 4. 0 (0. 0-13. 1) 9. 1 (0. 1-18. 2) 8. 4 (0. 0-17. 4) 4. 5 (0. 78. 2) 5. 8 (2. 09. 6) 9. 5 (5. 7-13. 3) Washington 8. 1 (5. 1-11. 0) 13. 8 (10. 8-16. 8) 7. 1 (4. 39. 9) 10. 7 (7. 9-13. 5) 13. 0 (10. 2-15. 8) 9. 8 (3. 1-16. 5) 10. 8 (4. 1-17. 5) 11. 0 (4. 3-17. 7) 8. 9 (5. 3-12. 5) 8. 7 (5. 1-12. 3) 12. 8 (9. 2-16. 4) West Virginia 4. 7 (2. 46. 9) 7. 0 (4. 89. 2) 3. 5 (1. 35. 7) 4. 7 (2. 46. 9) 7. 5 (5. 39. 7)  6. 0 (0. 0-15. 0) 3. 5 (0. 07. 2) 4. 9 (1. 28. 6) 8. 2 (4. 6-11. 9) Wisconsin 6. 2 (3. 58. 9) 9. 4 (6. 7-12. 1) 5. 7 (3. 18. 2) 7. 2 (4. 79. 8) 9. 1 (6. 6-11. 7) 7. 9 (0. 0-20. 3) 7. 7 (0. 0-20. 1) 5. 0 (0. 99. 0) 6. 8 (2. 7-10. 9) 9. 2 (5. 2-13. 3) Wyoming 8. 4 (5. 3-11. 5) 9. 9 (6. 8-13. 0) 7. 8 (4. 9-10. 7) 7. 6 (4. 7-10. 5) 11. 0 (8. 1-13. 9) 11. 0 (2. 8-19. 3) 9. 0 (0. 7-17. 3) 6. 1 (1. 7-10. 5) 6. 5 (2. 1-10. 9) 11. 7 (7. 4-16. 1) Abbreviations: CI = confidence interval; Ref = referent group. * W eighted percentages are presented.  Blacks and whit es are non-Hispanic; Hispanic persons could be of any race. Other racial/ethnic group not reported because of small sample sizes but included in overall estimates and estimates by other demographic characteristics.  Da ta where the sample sizes were <50 were considered unstable and were not reported.  p<0. 05 f or t-test comparing differences by demographic groups to the referent group. Morbidity and Mortality Weekly Report 1246 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and Preventionby race/ethnicity. In general, by state, lower percentages of blacks met recommendation for vegetable intake than did whites and Hispanics. Overall, a significantly higher percentage of persons with IPR >3. 49 met recommendations for vegetable intake than did those with IPR 3. 49, although no significant differences for meeting recommendations for fruit intake by IPR were observed. By state, a higher percentage of persons living in households with incomes in the highest category (IPR >3. 49) met the recommendation for vegetable intake than did persons living below or close to the poverty level (IPR <1. 25); these differences were significant in four states for fruits and 35 states for vegetables. Discussion Overall, the proportion of adults meeting fruit and veg - etable intake recommendations remained low in 2015, with more persons meeting recommendations for fruit intake than vegetable intake, and with substantial variations by state, age, sex, race/ethnicity, and IPR. Consistent with earlier studies of BRFSS data (5, 6), a higher percentage of women than men and a higher percentage of adults aged 51 years than persons aged 1830 years met recommendations for fruit and vegetable intake. Findings are also consistent with earlier work demon - strating larger IPR-related disparities in vegetable than fruit intake as well as a significantly higher prevalence of meeting recommendations for fruit intake among blacks and Hispanics than among whites (5) . However, this analysis did not observe previously reported significantly lower prevalences of meet - ing recommendations for vegetable intake among Hispanics and blacks compared with whites; that study measured the percentage of respondents who consumed vegetables more than three times per day rather than the ageand sex-specific cup-equivalent measure used in the current analysis. Because fruit and vegetable consumption affects mul - tiple health outcomes, including cardiovascular disease, type 2 diabetes, some cancers, and obesity (1) and is currently low among adults in all states and demographic subgroups, continued efforts are needed to identify and address barriers to fruit and vegetable consumption. A recent review identified several barriers, including high cost, limited availability and access, and perceived lack of preparation time (7, 8) . The CDC Guide to Strategies to Increase the Consumption of Fruits and Vegetables  identifies 10 strategies to increase access to and improve the availability of fruits and vegetables. Examples include starting or expanding farm-to-institution programs in childcare, schools, hospitals, workplaces, and other institu - tions; improving access to retail stores and markets that sell high quality fruits and vegetables; and ensuring access to fruits  https: //www. cdc. gov/obesity/downloads/fandv_2011_web_tag508. pdf. and vegetables in cafeterias and other food service venues in worksites, hospitals, and universities. To address cost, the U. S. Department of Agriculture Food Insecurity Nutrition Incentive (FINI) grant program** supports projects to increase the purchase of fruits and vegetables among low-income con-sumers participating in the Supplemental Nutrition Assistance Program, by providing incentives at the point of purchase; FINI projects are currently underway in 26 states.  The findings in this report are subject to at least six limita - tions. First, estimates did not include non-100% fruit juice or fried potatoes because the BRFSS questionnaire instructs respondents to exclude them. These foods were excluded from BRFSS because federal dietary guidelines recommend limiting foods and beverages with added sugars and solid fats such as these (1); estimates therefore represent intake from healthier sources. Including these additional sources of fruits and veg - etables results in 4%6% higher estimates for fruit intake and 30%44% higher estimates for vegetable intake (4) . Second, because the data are self-reported, they are subject to biases that might result in either overestimates or underestimates of actual fruit and vegetable consumption, and different demo - graphic groups might differentially misreport intake.  Third, the BRFSS survey excludes persons living in nursing homes, long-term care facilities, military installations, and correctional institutions, and thus these data are not generalizable to the entire U. S. population. Moreover, territories were excluded from this analysis because the scoring algorithms were derived from NHANES, which excludes territories. Fourth, using the scoring algorithms to estimate intake might have resulted in measurement error. However, previous analyses showed that applying prediction equations to 2011 BRFSS frequency data yielded estimates comparable to 20072010 national estimates that used more accurate 24-hour recalls (4) . Fifth, approxi - mately 13% of participants had fruit and vegetable data missing (58, 949 participants) . These respondents included a higher proportion of older adults and persons with IPR <1. 25, similar to a previous study (4) . A sensitivity analysis demonstrated that estimates did not change when persons with complete data for fruit intake, but not vegetables, or when persons with complete data for vegetable intake but not fruit were included. Finally, among the 375, 306 eligible participants who had complete information for fruit and vegetable intakes and resided in the study area, 13% (55, 891 participants) were excluded because they did not report household income. Estimated percent - ages of persons meeting recommendations were similar when ** https: //nifa. usda. gov/program/food-insecurity-nutrition-incentive-finigrant-program.  https: //nifa. usda. gov/program/food-insecurity-nutrition-incentive-fini-grant-program.  https: //dietassessmentprimer. cancer. gov/concepts/. Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1247 US Department of Health and Human Services/Centers for Disease Control and PreventionSummary What is already known about this topic? Consuming enough fruits and vegetables as part of an overall healthy diet reduces the risk of many chronic diseases, includ-ing cardiovascular disease, type 2 diabetes, some cancers, and obesity. However, the percentage of the adult population meeting fruit and vegetable intake recommendation is low. In 2013, 13. 1% of respondents met fruit intake recommendations and 8. 9% met vegetable recommendations. What is added by this report? Recent data show adults continue to consume too few fruits and vegetables; overall, 12. 2% met fruit intake recommendations and 9. 3% met vegetable intake recommendations during 2015. Consumption was lower among men, young adults, and adults with greater poverty, and varied by state. Among subgroups, the largest disparities in meeting the recommendation for fruit intake was by sex (15. 1% among women compared with 9. 2% among men), while the largest disparities in meeting the recommenda - tion for vegetable intake was by poverty (11. 4% among adults in the highest household income category compared with 7. 0% among adults below or close to the poverty level) . What are the implications for public health practice? States can use this information to inform the development of policies and programs that help all adults regardless of sociodemographic groups to consume more fruits and vegetables and thus help to prevent costly chronic diseases. income was imputed for persons with missing household income based on age, sex, and race/ethnicity. The estimates without imputation are presented to be consistent with previ - ous studies (2, 4) which allow states to compare estimates for surveillance purposes. Despite the positive health benefits of consuming fruits and vegetables, the findings from this study corroborate data showing that the vast majority of adults consume insufficient amounts, with lower intakes among men, young adults, and adults living in poverty. For most states, the only source of state-level nutritional data for adults is fruit and vegetable intake data from BRFSS. States can use this information to inform the development of policies and programs that help all adults regardless of sociode - mographic group to consume more fruits and vegetables and thus help prevent costly chronic diseases. Acknowledgments Survey participants; BRFSS state coordinators. Conflict of Interest No conflicts of interest were reported. 1Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, CDC. Corresponding author: Seung Hee Lee-Kwan, sleekwan@cdc. gov, 770-488-6020. References 1. US Department of Health and Human Services; US Department of Agriculture. 20152020 dietary guidelines for Americans. 8th ed. Washington, DC: US Department of Health and Human Services; US Department of Agriculture; 2015. https: //health. gov/ dietaryguidelines/2015/guidelines/ 2. M oore LV, Thompson FE. Adults meeting fruit and vegetable intake recommendationsUnited States, 2013. MMWR Morb Mortal Wkly Rep 2015; 64: 70913. 3. CDC. B ehavioral Risk Factor Surveillance System. Overview: BRFSS2015. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. https: //www. cdc. gov/brfss/annual_data/2015/pdf/overview_2015. pdf 4. M oore LV, Dodd KW, Thompson FE, Grimm KA, Kim SA, Scanlon KS. Using Behavioral Risk Factor Surveillance System data to estimate the percentage of the population meeting US Department of Agriculture food patterns fruit and vegetable intake recommendations. Am J Epidemiol 2015; 181: 97988. https: //doi. org/10. 1093/aje/kwu461 5. G rimm KA, Foltz JL, Blanck HM, Scanlon KS. Household income disparities in fruit and vegetable consumption by state and territory: results of the 2009 Behavioral Risk Factor Surveillance System. J Acad Nutr Diet 2012; 112: 201421. https: //doi. org/10. 1016/j. jand. 2012. 08. 030 6. B lanck HM, Gillespie C, Kimmons JE, Seymour JD, Serdula MK. T rends in fruit and vegetable consumption among U. S. men and women, 19942005. Prev Chronic Dis 2008; 5: A35. 7. P ollard J, Kirk SF, Cade JE. Factors affecting food choice in relation to fruit and vegetable intake: a review. Nutr Res Rev 2002; 15: 37387. https: //doi. org/10. 1079/NRR200244 8. Y eh MC, Ickes SB, Lowenstein LM, et al. Understanding barriers and facilitators of fruit and vegetable consumption among a diverse multi-ethnic population in the USA. Health Promot Int 2008; 23: 4251. https: // doi. org/10. 1093/heapro/dam044Morbidity and Mortality Weekly Report 1248 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and PreventionCDC Grand Rounds: Improving Medication Adherence for Chronic Disease Management  Innovations and Opportunities Andrea B. Neiman, PhD1; Todd Ruppar, PhD2; Michael Ho, MD, PhD3, 4; Larry Garber, MD5; Paul J. Weidle, PharmD6; Yuling Hong, MD, PhD1; Mary G. George, MD1; Phoebe G. Thorpe, MD7 Adherence to prescribed medications is associated with improved clinical outcomes for chronic disease manage - ment and reduced mortality from chronic conditions (1) . Conversely, nonadherence is associated with higher rates of hospital admissions, suboptimal health outcomes, increased morbidity and mortality, and increased health care costs (2) . In the United States, 3. 8 billion prescriptions are written annually (3) . Approximately one in five new prescriptions are never filled, and among those filled, approximately 50% are taken incorrectly, particularly with regard to timing, dosage, frequency, and duration (4) . Whereas rates of non - adherence across the United States have remained relatively stable, direct health care costs associated with nonadher - ence have grown to approximately $100$300 billion of U. S. health care dollars spent annually (5, 6) . Improving medication adherence is a public health priority and could reduce the economic and health burdens of many diseases and chronic conditions (7) . Understanding Medication Nonadherence Medication adherence is a complex behavior influenced by factors along the continuum of care, relating to the patient, providers, and health systems (8) . Patient-related factors include unintentional factors, which often worsen with increas - ingly complex medication regimens (e. g. , forgetting to take medication or obtain refills, or inadequate understanding of dose or schedules); and intentional factors (e. g. , active deci - sion to stop or modify a treatment regimen based on ability to pay, beliefs and attitudes about their disease, medication side effects, and expectations for improvement) (9) (Figure) . Additional patient-related barriers include lack of engagement in treatment decisions, impaired cognition (e. g. , related to aging or disease), substance abuse, depression, and other mental health conditions. Provider-related factors include barriers to communicating with patients and their caregivers, complex dosing regimens, and limited coordination of care among multiple providers. Health care system and service delivery factors include limited access to an appropriate provider for prescriptions or refills, restricted drug coverage, high costs and copayments, unclear medication labeling and instructions, limited availability of culturally appropriate patient education materials, and inadequate provider time to review benefits, risks, and alternatives to prescribed medications. Innovative Strategies to Improve Medication Adherence for Chronic Disease Management Successful efforts to improve rates of adherence often incor - porate multiple strategies across the continuum of care. A proven cost-effective strategy to reducing unintentional non - adherence is the use of pillboxes and blister packs to organize medication regimens in clear and simple ways (10) . Combining the ease of packaging with effective behavioral prompts, such as electronic pill monitors that can remind patients to take their medication and provide messages to health care provid - ers when a scheduled drug-dose is missed, supports increased medication adherence (11) . Interventions that include team-based or coordinated care have been shown to increase adherence rates. In a recent study, patients assigned to team-based care, including pharmacist-led medication reconciliation and tailoring; pharmacist-led patient education; collaborative care between pharmacist and primary care provider or cardiologist; and two types of voice messaging (educational and medication refill reminder calls) were significantly more adherent with their medication regi - men 12 months after hospital discharge (89%) compared with patients not receiving team-based care (74%) . Patients reported that team-based care improved their comfort in asking clarify - ing questions, raising concerns about their medication regimen, and collaborating in developing their treatment plan (12, 13) . Lowering economic barriers to prescribed medications also improves adherence rates. In 2007, Pitney-Bowes Corporation employees and beneficiaries with diabetes or vascular disease increased their medication adherence rates increased by 3%4% after the company eliminated or reduced health plan copays for cholesterol-lowering statins and the antiplatelet medication, clopidogrel (used to prevent heart attacks and strokes), compared with beneficiaries insured by another health plan with the same third-party prescription drugs administrator that did not reduce or eliminate copays for the same medica - tions. These improvements, while modest, could result in significant cost savings in the prevention of acute events (e. g. , hospitalizations) and progression of major chronic conditions if scaled to larger populations (14) . System-based strategies that address health disparities can improve clinical goals or reduce disease burden. For example, medication adherence is crucial for persons infected with human immunodeficiency virus (HIV), because treatment Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1249 US Department of Health and Human Services/Centers for Disease Control and PreventionFIGURE. Self-reported reasons* for nonadherence to recommended medication regimens  United States, 2013 0102030405060708090100 Forgot Ran out Away from homeTrying to save moneyHad side eectsWas too busyPrescription wasn't workingDidn't think prescription was neededDidn't like taking itPercentage of responses Source: Medication Adherence in America: A National Report Card, 2013. Adapted with permission. https: //www. ncpanet. org/pdf/reportcard/AdherenceReportCard_ Abridged. pdf. * P articipants could provide more than one response, and as such, categories are not mutually exclusive. lowers the amount of virus circulating in the blood, which improves the patients health and reduces the risk of trans - mitting HIV to others by >90% (15) . Interventions, such as CDCs Data to Care (16) strategy, that identify and re-engage nonadherent patients in care by linking them through the health department, their care providers, or both, improve the health of the individual and achieve the public health benefit of reducing HIV transmission (17) . Advances in health information technology can also improve medication adherence. In a 2011 study, providers using elec - tronic prescribing (e-prescribing) increased first-fill medication adherence by 10% compared with those using paper prescrip - tions (18) . Some e-prescribing software can monitor prescrip-tions dispensed or unfilled in near real-time, as well as send patients prompts when a new or refill prescription is available. These data allow providers to review current medication use with patients during office visits, identify gaps or barriers to adherence, and discuss workable solutions. Health information technology can also be used to show real-time impact of medication use on chronic conditions. Reliant Medical Group, a multispecialty group practice in Massachusetts, provided home blood pressure monitors to 200 of its patients. Patients uploaded blood pressure readings into their electronic health record. At office visits, providers were able to display trends of patients blood pressure, discuss barriers if blood pressure was not controlled and patients were not adherent, or add alternative drugs or lifestyle changes if pharmacy data indicated patients were adherent but their blood pressure was still poorly controlled. In addition, health information technology systems enabled providers to view medication coverage by insurer and choose lower cost medi - cations. Reliant also made complex prescribing algorithms easier to follow by establishing and incorporating treatment protocols for hypertension into the electronic health record. Using these and other strategies (Box), Reliant improved its hypertension control rate from 68% in 2011 to 79% in 2014 and was recognized as a Million Hearts Hypertension Control Champion in 2015 (19) . Opportunities in Medication Adherence Outcomes Although a range of interventions have demonstrated improved medication adherence and health outcomes during the study period, few studies have shown that these benefits were maintained over time (20) . Interventions that can sustain patient medication adherence are needed. One priority for developing sustainable strategies to improve medication adher - ence includes standardizing research methodology for both clinic and research settings. Currently, studies use a variety of measurement methods. Varying study methodologies prevents comparability across interventions, hinders wide application into clinical practice, and limits efforts that focus on patients with the greatest burden and need. Standardization might also help to understand both the dose-response and effectiveness of interventions over a longer time, increasing sustainability and reducing a waning effect at follow-up time points (21) . Morbidity and Mortality Weekly Report 1250 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and PreventionBOX. Strategies used by Reliant Medical Group (Massachusetts) to improve adherence to blood pressure medication and increase hypertension control rates Ensure that patient understands the benefits  E ducate about harms of uncontrolled hypertension and benefits of controlling hypertension  M ake culturally appropriate education materials available  A utomatically print educational information in the After-Visit Summary if patient has diagnosis of hypertension  S how patients graphs of their blood pressure trends during office visits and online electronic health record (EHR) portal. Use graphs to demonstrate challenges and successes with treatment regimens Choose lower cost medications  U se step-therapy protocols that are developed by a multidisciplinary team and are standardized across the organization  Contr ol access to pharmaceutical marketing  M ake the patients payer-specific formulary available in the EHR to inform medication selection  U se generic medication substitution  P rovide assistance in paying for medications (e. g. , RxAssist. org)  Consult social workers to assist with adherence barriers Minimize medication complexity  Choose once-a-day and combination medications  E ngage in dialogue about costs versus convenience (e. g. , pill-splitting can reduce cost but increase inconvenience) Monitor side effects  B e creative in addressing concerns e. g. , if concerned about swollen feet, use a diur etic, if appropriate e. g. , if concerned about medication causing abnormal potassium level, use a combined angiotensin-converting enzyme (ACE) inhibitor and a diuretic to normalize potassium When to monitor side effects  A t visits A t prescription renewals, using a standard documentation template After hospital discharge: automated aler ts for new medications  Consult pharmacists  F or complex medication regimens or side effects After hospital discharge regarding patients who are on high-risk medications Show effectiveness of the medications in lowering blood pressure  E mpower patient to record blood pressure readings at home  P rovide booklets to record readings  F or patients with financial hardships, provide free home blood pressure monitors  O ffer free blood pressure clinics  A utomatically upload blood pressure readings into the EHR Monitor medication adherence  E ncourage patients to document their medicationtaking behavior  U se EHR systems that can show medication fill history  A utomate adherence monitoring using payer medication claims  R eview adherence information during visits. Patients knowing that a clinician is monitoring adherence is at least as important as a patient seeing the results In addition, patient-specific tailored approaches to identify - ing reasons for nonadherence and aligning intervention efforts to address identified needs are needed. Outcomes might also be improved by recognizing populations at increased risk for nonadherence and addressing the broader reasons for their non - adherence, such as low health literacy. Health literacy is lower among the elderly, racial and ethnic minorities, and persons living in poverty (22) . Interventions to improve medication adherence could be more effective if patients health literacy, cultural background, and language preference and proficiency are taken into account when designing communication and patient education materials. Conclusion and Comments Medication adherence is critical to improving chronic disease outcomes and reducing health care costs. Successful strategies to improve medication adherence include 1) ensuring access to providers across the continuum of care and implementing Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1251 US Department of Health and Human Services/Centers for Disease Control and Preventionteam-based care; 2) educating and empowering patients to understand the treatment regimen and its benefits; 3) reduc-ing barriers to obtaining medication, including cost reduction and efforts to retain or re-engage patients in care; and 4) use of health information technology tools to improve decision-making and communication during and after office visits. Understanding root causes of medication nonadherence and cost-effective approaches that are applicable in diverse patient populations is essential to increasing adherence and improving long-term health impact. Conflict of Interest Dr. Ho reports grants from Veterans Health Administration during the conduct of the study; personal fees from Janssen, Inc. , personal fees from American Heart Association, outside the submitted work. Dr. Garber reports grants from Agency for Healthcare Research and Quality during the conduct of the study. 1Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC; 2Rush University, College of Nursing, Chicago, Illinois; 3Veterans Administration Medical Center, Denver, Colorado; 4University of Colorado Denver; 5Reliant Medical Group, Worcester, Massachusetts; 6U. S. Public Health Service Commissioned Corps, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; 7Office of the Associate Director for Science, CDC. Corresponding author: Andrea B. Neiman, afn1@cdc. gov, 770-488-8255. References 1. V rijens B, De Geest S, Hughes DA, et al. ; ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012; 73: 691705. https: //doi. org/10. 1111/j. 1365-2125. 2012. 04167. x 2. D iMatteo MR. Variations in patients adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 2009. https: //doi. org/10. 1097/01. mlr. 0000114908. 90348. f9 3. C utler DM, Everett W. Thinking outside the pillboxmedication adherence as a priority for health care reform. N Engl J Med 2010; 362: 15535. https: //doi. org/10. 1056/NEJMp1002305 4. O sterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 48797. https: //doi. org/10. 1056/NEJMra050100 5. I uga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy 2014; 7: 3544 10. 2147/RMHP. S19801. 6. V iswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012; 157: 78595. https: //doi. org/10. 7326/0003-4819-157-11-201212040-00538 7. N ational Center for Health Statistics. National health expenditures, average annual percent change, and percent distribution, by type of expenditure: United States, selected years 19602014. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2015. https: //www. cdc. gov/nchs/data/hus/2015/094. pdf 8. G ellad WF, Grenard K, McGlynn EA. A review of barriers to medication adherence: a framework for driving policy options. Santa Monica, CA: RAND; 2009. https: //www. rand. org/content/dam/rand/pubs/ technical_reports/2009/RAND_TR765. pdf 9. Le hane E, McCarthy G. Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper. Int J Nurs Stud 2007; 44: 146877. https: // doi. org/10. 1016/j. ijnurstu. 2006. 07. 010 10. R uppar TM, Delgado JM, Temple J. Medication adherence interventions for heart failure patients: a meta-analysis. Eur J Cardiovasc Nurs 2015; 14: 395404. https: //doi. org/10. 1177/1474515115571213 11. C hecchi KD, Huybrechts KF, Avorn J, Kesselheim AS. Electronic medication packaging devices and medication adherence: a systematic review. JAMA 2014; 312: 123747. https: //doi. org/10. 1001/ jama. 2014. 10059 12. Lamber t-Kerzner A, Havranek EP, Plomondon ME, et al. Perspectives of patients on factors relating to adherence to post-acute coronary syndrome medical regimens. Patient Prefer Adherence 2015; 9: 10539. https: //doi. org/10. 2147/PPA. S84546 13. H o PM, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med 2014; 174: 18693. https: //doi. org/10. 1001/ jamainternmed. 2013. 12944 14. Choudhr y NK, Fischer MA, Avorn J, et al. At Pitney Bowes, valuebased insurance design cut copayments and increased drug adherence. Health Aff (Millwood) 2010; 29: 19952001. https: //doi. org/10. 1377/ hlthaff. 2010. 0336 15. Cohen MS, Chen YQ, McCauley M, et al. ; HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016; 375: 8309. https: //doi. org/10. 1056/NEJMoa1600693 16. CDC. Data to care. Using HIV surveillance data to support the HIV care continuum. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https: //effectiveinterventions. cdc. gov/en/ HighImpactPrevention/PublicHealthStrategies/DatatoCare. aspx 17. C repaz N, Dong X, Chen M, Hall HI. Examination of HIV infection through heterosexual contact with partners who are known to be HIV infected in the United States. AIDS 2017; 31: 16414. https: //doi. org/10. 1097/QAD. 0000000000001526 18. S urescripts. The national progress report on e-prescribing and interoperable health care. Arlington, VA: Surescripts; 2011. 19. M illion Hearts. Reliant Medical Group strategizes for the road to success. Empowering patients to control hypertension. Atlanta, GA: US Department of Health and Human Services, CDC, Million Hearts; 2017. https: //millionhearts. hhs. gov/files/Champions-SS-Reliant. pdf 20. D emonceau J, Ruppar T, Kristanto P, et al. ; ABC project team. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs 2013; 73: 54562. https: //doi. org/10. 1007/s40265-013-0041-3 21. Boswor th HB, Granger BB, Mendys P, et al. Medication adherence: a call for action. Am Heart J 2011; 162: 41224. https: //doi. org/10. 1016/j. ahj. 2011. 06. 007 22. Le wey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J 2013; 165: 66578. https: //doi. org/10. 1016/j. ahj. 2013. 02. 011Morbidity and Mortality Weekly Report 1252 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and PreventionGlobal Routine Vaccination Coverage, 2016 Leora R. Feldstein, PhD1, 2; Stephanie Mariat, MSc3; Marta Gacic-Dobo, MSc3; Mamadou S. Diallo, PhD4; Laura M. Conklin, MD2; Aaron S. Wallace, MPH2 The Global Vaccine Action Plan 20112020 (GVAP) (1), endorsed by the World Health Assembly in 2012, calls on all countries to reach 90% national coverage for all vaccines in the countrys routine immunization schedule by 2020. CDC and the World Health Organization (WHO) evaluated the WHO and United Nations Childrens Fund (UNICEF) global vaccination coverage estimates to describe changes in global and regional coverage as of 2016. Global coverage estimates for the third dose of diphtheria and tetanus toxoids and pertus - siscontaining vaccine (DTP3), the third dose of polio vaccine, and the first dose of measles-containing vaccine (MCV1) have ranged from 84% to 86% since 2010. The dropout rate (the proportion of children who started but did not complete a vaccination series), an indicator of immunization program performance, was estimated to be 5% in 2016 for the 3-dose DTP series, with dropout highest in the African Region (11%) and lowest in the Western Pacific Region (0. 4%) . During 20102016, estimated global coverage with the second MCV dose (MCV2) increased from 21% to 46% by the end of the second year of life and from 39% to 64% when older age groups (314 years) were included (2) . Improvements in national immunization program performance are necessary to reach and sustain high vaccination coverage to increase protection from vaccine-preventable diseases for all persons. In 1974, the World Health Organization (WHO) established the Expanded Program on Immunization to ensure that all children have access to four routinely recommended vaccines that protect against six diseases (3) : bacillus Calmette-Gurin vaccine (to protect against tuberculosis), polio, MCV, and DTP. WHO and UNICEF derive national coverage estimates through an annual country-by-country review of all available data, including administrative and survey-based coverage (4, 5) . Typically, only doses administered through routine immuniza - tion visits are counted. * This report updates a previous report (6) and presents global, regional, and national vaccination * F or a given vaccine, the administrative coverage is the number of vaccine doses administered to persons in a specified target group divided by the estimated target population. Doses administered through routine immunization visits are counted, but doses administered through supplemental immunization activities (mass campaigns), usually are not. During vaccination coverage surveys, a representative sample of households is visited, and caregivers of children in a specified target age group (e. g. , aged 1223 months) are interviewed. Dates of vaccination are transcribed from the childs home-based record, recorded based on caregiver recall, or transcribed from health facility records. Survey-based vaccination coverage is calculated as the proportion of persons in a target age group who received a vaccine dose. coverage estimates and trends as of 2016. It also estimates the proportion of surviving infants who did not receive any DTP doses (referred to as left-out) and the proportion that received 1 or 2 doses of DTP, but did not receive the third dose of DTP (dropped out), using the DTP 3-dose series as an indicator of overall program performance (3, 4) . Globally, 116. 5 million children received DTP3 in 2016 compared with 24. 2 million in 1980 (Figure), a 300% increase in global DTP3 coverage from 21% to 86%. In 2016, DTP3 coverage ranged from 74% in the WHO African Region to 97% in the Western Pacific Region (Table 1) . In all regions, DTP3 coverage has remained stable or increased during 20152016. National DTP3 coverage estimates var - ied from 19% to 99%. Overall, 130 (67%) of 194 countries achieved 90% national DTP3 coverage in 2016, an increase from 128 (66%) countries the previous year (2) . National DTP3 coverage was 80%89% in 29 countries, 70%79% in 15 countries and <70% in 20 countries. Among the 19. 5 million children worldwide who did not receive 3 DTP doses during the first year of life, 11. 8 million (61%) lived in 10 countries: Nigeria (18%), India (16%), Pakistan (7%), Indonesia (6%), Ethiopia (4%), the Democratic Republic of the Congo (3%), Iraq (3%), Angola (2%), Brazil (1%), and South Africa (1%) . Among approximately 20 million children who did not complete the 3-dose DTP series in 2016, 12. 9 million (66%) did not receive any DTP doses, a decrease from 79. 4 million in 1980, and 6. 6 million (34%) started, but dropped out and did not complete the DTP series (Figure) . The largest proportions of infants who were left out were in the WHO African (17%) and Eastern Mediterranean (15%) Regions (Table 2) . National DTP1 to DTP3 dropout rates varied from 0% to 55%, with highest dropout in the African Region (11%) and lowest in the Western Pacific Region (0. 4%) (Table 2) . MCV1 coverage in 2016 ranged from 72% in the African Region to 96% in the Western Pacific Region (Table 1) and from 20% to 99% by country. During 20152016, MCV1 coverage has remained stable or increased in all regions. Globally, 123 (63%) countries achieved the GVAP 2020 target of 90% national MCV1 coverage (7) . MCV2 coverage by WHO region varied from 24% (African Region) to 93% (Western Pacific Region), including countries that have not yet introduced MCV2 (Table 1) . In four of six WHO regions (African, Region of the Americas, Eastern Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1253 US Department of Health and Human Services/Centers for Disease Control and PreventionFIGURE. Coverage with the first and third doses of diphtheria and tetanus toxoids and pertussiscontaining vaccine (DTP1 and DTP3) and the number of children who were left out (received no DTP doses), dropped out (received 1 or 2 DTP doses), or completed 3 DTP doses  worldwide, 19802016 0102030405060708090100 20, 000, 000 40, 000, 000 60, 000, 000 80, 000, 000 100, 000, 000 120, 000, 000 140, 000, 000 1980 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016Vaccination coverage (%) No. of children Year0Left-out (received zero DTP doses) Dropped out (received 1 or 2 DTP doses) Complete (received 3 DTP doses) DTP1 coverage DTP3 coverage Mediterranean, and South-East Asia), MCV2 coverage increased in 2016 compared with 2015, because of both an increase in coverage in multiple countries, as well as an increase in the number of countries introducing MCV2. Globally, MCV1 coverage was 85% and MCV2 coverage was 64% in 2016 (estimated dropout = 21%) . MCV1 to MCV2 differ-ence was highest in the African Region (48%) and lowest in the Western Pacific Region (3%) (Table 2) . This difference represents both lack of MCV2 introduction (34 countries not yet introduced) and differences in program performance. Among new and underused vaccines, global coverage increased during 20102016 for completed series  of rotavirus vaccine (8% to 25%), pneumococcal conjugate vaccine (PCV) to prevent infections with Streptococcus pneumoniae (11% to 42%), rubella vaccine (35% to 47%), Haemophilus influenzae type b (Hib) vaccine (42% to 70%), and hepatitis B vaccine (74% to 84%) (Table 1), as a result of improvements in national coverages rates and new country introductions. Discussion Substantial progress in global routine vaccination coverage has been made since 1974, even as the population of surviving infants has increased. As a result, approximately 123 million children, 91% of the global population of surviving infants, received at least 1 dose of DTP vaccine during their first year of life in 2016, and nearly 117 million (86%) completed the DTP series. However, 64 (33%) countries still have not met  T wo rotavirus vaccines are currently licensed; the monovalent vaccine is administered as a 2-dose series, and the pentavalent vaccine is administered as a 3-dose series. the GVAP target of 90% national DTP3 coverage, and 71 countries (37%) have not reached the 20122020 Global Measles and Rubella Strategic Plan target of 90% national MCV1 coverage (7) . Moreover, DTP3 and MCV1 coverage rates have remained stagnant since 2010 (2) . Among the eight countries with DTP3 coverage <50% in 2016 (Central African Republic, Chad, Equatorial Guinea, Nigeria, Somalia, South Sudan, Syria, and Ukraine), nearly all are in conflict or facing serious economic turmoil. Consequently, maintaining coverage with existing vaccines and introducing new vaccines in these countries is particularly challenging. In light of these challenges, improving initiation of vac - cination and completion of the series for all recommended vaccines is an integral step toward improving vaccination coverage globally, particularly in the WHO African, Eastern Mediterranean, and South-East Asia Regions. In these three regions in 2016, 11 million infants did not receive their first dose of DTP vaccine, and 18 million did not receive their first dose of MCV. Six million infants started the DTP series but did not complete it, and 22 million started, but did not complete the MCV series (Table 2) . Ensuring that these infants receive the full number of doses of recommended vaccines will be critical to preventing early childhood mortality and morbidity during adolescence and adulthood, and it will provide indirect protection to the whole community. The findings in this report are subject to at least two limi - tations. First, numerator and denominator biases might be present because of outdated national census and limited vac - cination coverage reporting capabilities at lower administrative levels, which might result in overestimates or underestimates of Morbidity and Mortality Weekly Report 1254 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and PreventionTABLE 1. Vaccination coverage, by vaccine and World Health Organization region  worldwide, 2016 VaccineNo. (%) countries with vaccine in schedule% Coverage, * by region Global (all regions) African AmericasEastern Mediterranean European South-East Asia Western Pacific BCG 158 (81) 88 81 95 87 91 89 95 HepB BD 84 (43) 39 10 66 22 39 34 83 HepB3 185 (95) 84 74 89 80 81 88 92 DTP3 194 (100) 86 74 91 80 92 88 97 Hib3 191 (98) 70 74 90 80 77 80 28 Pol3 194 (100) 85 73 92 80 94 87 95 Rota last 84 (43) 25 43 74 23 23 3 2 PCV3 129 (66) 42 65 84 48 62 9 14 MCV1 194 (100) 85 72 92 77 93 87 96 RCV1 151 (78) 47 13 92 46 93 15 96 MCV2 160 (82) 64 24 54 69 88 75 93 Abbreviations: BCG = Bacillus Calmette-Gurin vaccine; DTP3 = third dose of diphtheria and tetanus toxoids and pertussis vaccine; HepB BD = birth dose of hepatitis B vaccine; HepB3 = third dose of hepatitis B vaccine; Hib3 = third dose of Haemophilus influenzae type b vaccine; MCV1 = first dose of measles-containing vaccine; MCV2 = second dose of MCV; PCV3 = 3 doses of pneumococcal conjugate vaccine; Pol3 = third dose of polio vaccine; RCV1 = first dose of rubella-containing vaccine; Rota last = final dose of rotavirus vaccination series. * BC G coverage based on 158 countries with BCG in the national schedule; coverage for all other vaccines based on 194 countries (global) or all countries in the specified region. TABLE 2. Vaccination coverage and dropout proportions for diphtheria and tetanus toxoids and pertussiscontaining vaccine and measlescontaining vaccine, by World Health Organization (WHO) region  worldwide, 2016 WHO regionDTP1 coverage %DTP1 left-out* % (No.) DTP3 coverage %DTP1 to DTP3 dropout % (No.) MCV1 coverage %MCV1 left-out* % (No.) MCV2 coverage %MCV1 to MCV2 difference % (No.) Global (all regions) 91 9 (12. 9M) 86 5 (6. 6M) 85 15 (20. 8M) 64 21 (29. 1M) African 83 17 (5. 9M) 74 11 (3. 1M) 72 28 (9. 6M) 24 48 (16. 2M) Americas 95 5 (0. 7M) 91 4 (0. 6M) 92 8 (1. 2M) 54 38 (6. 0M) Eastern Mediterranean 85 15 (2. 5M) 80 6 (0. 8M) 77 24 (3. 9M) 69 8 (1. 4M) European 95 5 (0. 5M) 92 3 (0. 3M) 93 7 (0. 8M) 88 5 (0. 5M) South-East Asia 93 7 (2. 6M) 88 5 (1. 6M) 87 13 (4. 5M) 75 12 (4. 3M) Western Pacific 97 3 (0. 7M) 97 0. 4 (0. 08M) 96 4 (0. 9M) 93 3 (4. 3M) Abbreviations: DTP1 = first dose of diphtheria and tetanus toxoids and pertussis vaccine; DTP3 = third dose of DTP; MCV1 = first dose of measles-containing vaccine; MCV2 = second dose of MCV; M = million. * L eft-out = the proportion of surviving infants who did not receive any doses of the specified vaccine.  Dr opout = those who received 1 or 2 DTP doses but not the third dose of DTP.  I ncludes 34 countries that either have not introduced MCV2 or that do not report MCV2 coverage; 65% of these countries are located in the African Region.  Diff erence = children who received MCV1 but not MCV2. administrative vaccination coverage. Second, survey data might suffer from recall bias and the data might not be generalizable to the larger population (4) . Demographic barriers (minority ethnicity, parents lack of education, and low socioeconomic status), populations living in difficult-to-reach areas, programmatic challenges such as vaccine stock-outs, and conflict continue to prevent certain children from receiving the benefits of being fully vaccinated (8) . At district or country levels, program costs and insufficient political will also contribute to problems with vaccine access and completion of vaccination series (9) . Strategies to improve vaccine accessibility (i. e. , reducing the number of left-out children) might be different from those used to minimize drop - out. To improve accessibility, steps are needed to ensure that hard-to-reach populations are identified and that vaccination sessions are made consistently accessible. Program managers need to use effective vaccine management practices to avoid stock-outs, and health workers need to be available and well trained to provide acceptable services to the community (10) . To minimize dropouts, interventions might include promoting demand for vaccination, particularly in culturally hard-to-reach populations; provider communication to caregivers about the benefits of vaccines and addressing any vaccine safety concerns; reminder or recall strategies to ensure that caregivers return for future vaccinations, and defaulter tracking strategies to identify children who have failed to return for a recommended vaccination. Improving both initiation of vaccination and completion of the series is essential for establishing sustainable national immunization programs and to eliminating prevent - able diseases and deaths among children. Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1255 US Department of Health and Human Services/Centers for Disease Control and PreventionSummary What is already known about this topic? In 1974, the World Health Organization (WHO) established the Expanded Program on Immunization to ensure that all children have access to routinely recommended vaccines. Since then, global coverage with vaccines to prevent tuberculosis, diphthe - ria, tetanus, pertussis, poliomyelitis, and measles has increased from <5% to 85% and additional vaccines against hepatitis B, Haemophilus influenzae type B, Streptococcus pneumoniae, rotavirus, and rubella have been included in vaccine recommen - dations introduced in multiple countries. What is added by this report? Global coverage with the third dose of diphtheria and tetanus toxoids and pertussiscontaining vaccine, the third dose of polio vaccine, and first dose of measles-containing vaccine coverage has remained unchanged at 84%86% since 2010. Among new or underused vaccines, global coverage increased during 20102016 for completed vaccine series against rotavirus (8% to 25%), Streptococcus pneumoniae (11% to 42%), rubella (35% to 47%), Haemophilus influenzae type B (42% to 70%) and hepatitis B vaccine (74% to 84%) . Vaccination coverage varies widely across WHO regions, countries, and districts, with decreased access to vaccination and completion of vaccination series in low-income countries and conflict areas compared with that in other countries. What are the implications for public health practice? Since 1974, there has been substantial progress in global vaccination; however, in recent years, coverage rates have remained static. This indicates the need to move beyond existing practices to improve access to vaccinations for hard-to-reach populations. Interventions include strengthening caregiver demand for vaccination, provider communication to caregivers about the benefits of vaccines and addressing any vaccine safety concerns; reminder or recall strategies to ensure caregivers return for future vaccinations, and defaulter tracking strategies to identify children who have failed to return for a recommended vaccination. Conflict of Interest No conflicts of interest were reported. 1Epidemic Intelligence Service, CDC; 2Global Immunization Division, CDC; 3Department of Immunization, Vaccines and Biologicals, World Health Organization; 4Division of Data, Research and Policy, United Nations Childrens Fund. Corresponding author: Leora R. Feldstein, nqw5@cdc. gov, 404-718-6811. References 1. W orld Health Organization. Global vaccine action plan 20112020. Geneva, Switzerland: World Health Organization; 2013. http: //www. who. int/immunization/global_vaccine_action_plan/en/ 2. W orld Health Organization. Immunization, vaccines and biologicalsdata, statistics and graphs. Geneva, Switzerland: World Health Organization; 2016. http: //www. who. int/immunization/ monitoring_surveillance/en 3. Uwizihiw e JP, Bock H. 40th anniversary of introduction of expanded immunization program (EPI) : a literature review of introduction of new vaccines for routine childhood immunization in Sub-Saharan Africa. Int J Vaccines Vaccin 2015; 1: 123. http: //medcraveonline. com/IJVV/ IJVV-01-00004. php 4. B urton A, Monasch R, Lautenbach B, et al. WHO and United Nations Childrens Fund estimates of national infant immunization coverage: methods and processes. Bull World Health Organ 2009; 87: 53541. https: //doi. org/10. 2471/BLT. 08. 053819 5. The World Bank. World Bank country and lending groups. New York, NY: The World Bank; 2016. https: //datahelpdesk. worldbank. org/knowledgebase/ articles/906519-world-bank-country-and-lending-groups 6. Casey RMDL, D umolard L, Danovaro-Holliday MC, et al. Global routine vaccination coverage, 2015. MMWR Morb Mortal Wkly Rep 2016; 65: 12703. https: //doi. org/10. 15585/mmwr. mm6545a5 7. W orld Health Organization. Global measles and rubella strategic plan: 20122020. Geneva, Switzerland: World Health Organization; 2012. http: //measlesrubellainitiative. org/wp-content/uploads/2013/06/Measles-Rubella-Strategic-Plan. pdf 8. Rainey JJ, Watkins M, Ryman TK, Sandhu P, Bo A, Banerjee K. Reasons related to non-vaccination and under-vaccination of children in low and middle income countries: findings from a systematic review of the published literature, 19992009. Vaccine 2011; 29: 821521. https: // doi. org/10. 1016/j. vaccine. 2011. 08. 096 9. LaF ond A, Kanagat N, Steinglass R, Fields R, Sequeira J, Mookherji S. Drivers of routine immunization coverage improvement in Africa: findings from district-level case studies. Health Policy Plan 2015; 30: 298308. https: //doi. org/10. 1093/heapol/czu011 10. P hillips DE, Dieleman JL, Lim SS, Shearer J. Determinants of effective vaccine coverage in low and middle-income countries: a systematic review and interpretive synthesis. BMC Health Serv Res 2017; 17: 681. https: // doi. org/10. 1186/s12913-017-2626-0Morbidity and Mortality Weekly Report 1256 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and PreventionProgress in Rubella and Congenital Rubella Syndrome Control and Elimination  Worldwide, 20002016 Gavin B. Grant, MD1; Susan E. Reef, MD1; Minal Patel, MD2; Jennifer K. Knapp, PhD1; Alya Dabbagh, PhD2 Although rubella virus infection usually causes a mild fever and rash illness in children and adults, infection during pregnancy, especially during the first trimester, can result in miscarriage, fetal death, stillbirth, or infants with a constella - tion of congenital malformations known as congenital rubella syndrome (CRS) (1) . Rubella is a leading vaccine-preventable cause of birth defects. Preventing these adverse pregnancy out - comes is the focus of rubella vaccination programs. In 2011, the World Health Organization (WHO) updated guidance on the preferred strategy for introduction of rubella-containing vaccine (RCV) into national immunization schedules and recommended an initial vaccination campaign, usually target - ing children aged 9 months14 years (1) . The Global Vaccine Action Plan 20112020 (GVAP), endorsed by the World Health Assembly in 2012, includes goals to eliminate rubella in at least five of the six WHO regions by 2020 (2) . This report updates a previous report (3) and summarizes global progress toward rubella and CRS control and elimination from 2000 to 2016. As of December 2016, 152 (78%) of 194 countries had introduced RCV into the national immunization schedule, representing an increase of 53 countries since 2000, including 20 countries that introduced RCV after 2012. Reported rubella cases declined 97%, from 2000 (670, 894 cases in 102 countries) to 2016 (22, 361 cases in 165 countries) . The Region of the Americas has achieved rubella and CRS elimination (verified in 2015) . Rubella and CRS elimination goals have been set by the European Region (target date: 2015) and Western Pacific Region (target date to be determined), whereas the South-East Asia Region has a rubella and CRS control target. Neither the African Region nor the Eastern Mediterranean Region has set regional rubella goals or targets. To achieve the 2020 GVAP rubella elimination goals, RCV introduction needs to continue when country criteria indicat-ing readiness for introduction are met, and rubella and CRS surveillance needs to be strengthened to ensure that progress toward elimination targets are measured. Because rubella cases are detected through measles surveillance, and because rubella vaccine is usually delivered as a combined measles-rubella vac - cine, elimination activities for both diseases are programmati-cally linked, and measles elimination activities can be leveraged to support rubella elimination. Rubella and CRS surveillance are necessary to assess disease burden before RCV introduction, to monitor disease burden and epidemiology after introduction, to identify pregnant women infected with rubella virus who require follow-up to assess pregnancy outcomes, and to identify, diagnose, and manage CRS-affected infants. Countries report information on immunization schedules, vaccination campaigns, number of vaccine doses administered through routine immunization services, and other WHO monitoring data (4) to WHO and the United Nations Childrens Fund (UNICEF) each year using the Joint Reporting Form (JRF) . Surveillance data, including number of cases of rubella and CRS, are also reported to WHO and UNICEF through the JRF using standard case definitions (5) . For this report, JRF data from the period 20002016 were analyzed; analyses focused on data from 2000 (initiation of accelerated measles control activities), 2012 (the new phase of rubella elimination), 2014 (the last worldwide update), and 2016 (the most recent data available) . Immunization Activities Global coverage with RCV increased from 21% in 2000 to 40% in 2012 and to 47% in 2016. In 2000, just over half (99, 51%) of countries had introduced RCV into their immuniza - tion schedule; by the end of 2012, more than two thirds (132, 68%) of countries were using RCV. By 2014, at the time of the last worldwide update (3), eight additional countries intro - duced RCV, bringing the total number of countries using RCV to 140 (72%) . At that time, 44 of the 54 countries that had not yet introduced RCV were eligible for support from Gavi, the Vaccine Alliance (Gavi) . * During 20152016, 12 of these 54 countries introduced RCV, so that by the end of 2016, RCV had been introduced into the routine immunization schedule in 152 (78%) countries, including 13 (28%) in the African Region, 16 (76%) in the Eastern Mediterranean Region, eight (73%) in the South-East Asia Region, and all 115 countries in the Region of the Americas, European Region, and Western Pacific Region (Table 1) . Among the 12 countries that intro - duced RCV during 20152016, six received Gavi support for the introduction, and six (among the 10 countries not eligible for Gavi support) introduced the vaccine using other support (Figure) (Table 2) . * F our countries that had recently increased income levels above the support threshold applied and were accepted for Gavi immunization services support, but did not introduce RCV by the end of 2016. Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1257 US Department of Health and Human Services/Centers for Disease Control and PreventionTABLE 1. Global progress in rubella and congenital rubella syndrome (CRS) control and elimination  World Health Organization (WHO) Regions, 2000, 2012, and 2016 CharacteristicWHO region (No. of countries) AFR (47) AMR (35) EMR (21) EUR (53) SEAR (11) WPR (27) Worldwide (194) Regional rubella/CRS target None Elimination None Elimination Control Elimination None No. of countries with RCV in schedule 2000 2 31 12 40 2 12 99 2012 3 35 14 53 5 22 132 2016 13 35 16 53 8 27 152 Regional rubella vaccination coverage (%) 2000 0 85 23 60 3 11 21 2012 0 94 38 95 5 86 40 2016 13 92 46 93 15 96 47 No. of countries reporting rubella cases2000 7 25 11 41 3 15 102 2012 41 35 19 47 11 23 176 2016 44 30 18 45 11 17 165 No. of reported rubella cases2000 865 39, 228 3, 122 621, 039 1, 165 5, 475 670, 894 2012 10, 850 15 1, 681 30, 579 6, 877 44, 275 94, 277 2016 4, 157 1 2, 037 359 10, 361 5, 446 22, 361 No. of countries reporting CRS cases2000 3 18 6 34 2 12 75 2012 20 35 9 43 6 17 130 2016 21 30 10 42 10 12 125 No. of reported CRS cases2000 0 80 0 47 26 3 156 2012 69 3 20 62 14 134 302 2016 14 0 9 6 319 19 367 Abbreviations: AFR = African Region; AMR = Region of the Americas; CRS = congenital rubella syndrome; EMR = Eastern Mediterranean Region; EUR = European Region; RCV = rubella-containing vaccine; SEAR = South-East Asia Region; WPR = Western Pacific Region. FIGURE. Rubella-containing vaccine (RCV) introduction and status of rubella elimination, * by country  World Health Organization, 2016 RCV in routine immunization schedule and rubella veri/f_ied as eliminated RCV in routine immunization schedule and rubella not veri/f_ied as eliminatedRCV not in routine immunization scheduleNot applicable * Only the E uropean Region and the Region of the Americas had established a process for verifying rubella elimination by July 2017. Morbidity and Mortality Weekly Report 1258 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and PreventionTABLE 2. Characteristics of rubella-containing vaccine introduction by 12 countries that introduced the vaccine during 20152016  World Health Organization (WHO) CountryWHO regionYear RCV introduced into routine schedule*Introductory vaccination campaign*Gavi support status for introduction YearTarget age groupTarget population% vaccination coverage by report% vaccination coverage by survey Botswana AFR 2016 2016 9 mos14 yrs 706, 504 95 97 No Burkina Faso AFR 2015 2014 9 mos14 yrs 8, 481, 625 106 Not reported Yes Burma SEAR 2015 2015 9mos14 yrs 13, 160, 764 94 Not done Yes Namibia AFR 2016 2016 9 mos39 yrs 1, 859, 857 103 Not done No Papua New Guinea WPR 2015 20152016 9 mos14 yrs 1, 976, 335 63 Not done Yes Sao Tome and Principe AFR 2016 2016 9 mos14 yrs 72, 449 107Not done No Swaziland AFR 2016 2016 9 mos14 yrs 412, 874 90 94 No Timor-Leste SEAR 2016 2015 6 mos14 yrs 501, 832 97 95 No Vanuatu WPR 2015 2015 114 yrs 103, 676 98 Not done No Vietnam WPR 2015 20142015 114 yrs 19, 740, 181 98 Not done Yes Yemen EMR 2015 2014 9 mos14 yrs 11, 368, 968 85 Not done Yes Zimbabwe AFR 2015 2015 9 mos14 yrs 5, 203, 976 103 Not done Yes Abbreviations: AFR = African Region; EMR = Eastern Mediterranean Region; Gavi = Gavi, the Vaccine Alliance; RCV = Rubella-containing vaccine; SEAR = South-East Asia Region; WHO = World Health Organization; WPR = Western Pacific Region. * I ntroductory campaigns and introduction of the vaccine into the routine schedule can occur in different years, with introduction recommended to occur immediately following the campaign.  V alues >100% indicate that the intervention reached more persons than the estimated target population. Routine administration of RCV is recommended with the first routine dose of measles-containing vaccine (MCV1) (i. e. , as a combination vaccine or simultaneously, at the same visit); this recommendation has been implemented in 144 (95%) of the 152 countries that have introduced the vaccine. Based on individual countries MCV vaccination schedules, the first RCV dose is scheduled at age 811 months in 27 (18%) coun - tries and at age 1218 months in 125 (83%) countries. RCV is provided as a combination vaccine with measles vaccine in 30 (20%) countries and combined with measles and mumps vaccine (with or without varicella vaccine) in 122 (80%) coun - tries; one country administers rubella vaccine simultaneously with combined measles and mumps vaccine. Surveillance Activities During 20002016, the number of countries reporting rubella cases (including those reporting zero cases) increased 42%, from 102 in 2000 to 176 in 2012, but the number of reporting countries declined 6%, to 165 in 2016 (Table 1) . The number of countries reporting CRS cases increased 42%, from 2000 (75 countries) to 2012 (130), then decreased 4% to 125 countries in 2016. The number of reported CRS cases reported increased, especially in the South-East Asia Region, with the establishment of CRS surveillance systems. Among all 152 countries where RCV had been introduced by December 2016, 126 (83%) reported rubella data, and 110 (72%) reported CRS data. In 2016, 22, 361 rubella cases were reported to WHO, a 97% decrease from 670, 894 cases reported in 2000, and a 76% decrease from 94, 277 cases reported in 2012 (Table 1) . T wo regions (Region of the Americas and European Region) have regional verification commissions to verify rubella elimination. In the Region of the Americas, the last endemic rubella and CRS cases were reported in 2009, and the region was verified free of endemic rubella virus transmission in April 2015 (6) . In the European Region, 33 (62%) of 53 countries were declared free of endemic rubella virus transmission in 2016. The number of rubella virus genotype sequences identi - fied globally from reported rubella cases increased from 33 sequences submitted by six countries in 2000, to 137 sequences submitted by 21 countries in 2012, to 188 sequences submit - ted by 16 countries in 2016. Of the 13 known genotypes of rubella virus, three genotypes were detected circulating in 2016. Discussion In 2011, a new phase of accelerated rubella control and CRS prevention began, with updated WHO guidance for RCV introduction, Gavi funding for RCV introduction in eligible countries, and establishment of rubella elimination goals in the GVAP. Taking advantage of these opportunities and leveraging measles elimination activities, RCV has been introduced into the national immunization schedules in 53 countries since 2000; 20 (37%) of these countries introduced the vaccine during 20132016. By the end of 2016, with technical and financial support from partners, 78% of all countries glob - ally had introduced RCV into their national immunization schedules, advancing progress toward elimination. Although more than three fourths of countries have introduced RCV, because of differences in country population sizes, less than half (47%) of infants worldwide are vaccinated against rubella. Among the 42 countries that have not yet introduced RCV, nine have not achieved >80% coverage with MCV through routine immunization services or vaccination campaigns, which is a prerequisite to ensure safe RCV introduction (1); Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1259 US Department of Health and Human Services/Centers for Disease Control and Preventiontherefore, these nine countries need to improve routine immu - nization services and vaccination campaign quality. Among countries that have achieved at least 80% MCV1 coverage and are deciding whether to introduce RCV, country-specific data on CRS burden is often requested by national advisory groups or program managers to provide justification for long-term sustainable financing of RCV. Among middle-income countries that do not receive significant donor support, the financial sustainability of inclusion of RCV in the national immunization schedule is especially important to determine before embarking on introduction. Once RCV is introduced, optimizing its use is essential to reaching regional and national rubella and CRS control or elimination targets. Among the 152 countries that have introduced RCV, the vaccine was admin - istered with MCV1 in 144 (95%) countries, facilitating the highest possible RCV coverage. In resource-limited settings, identification of the appropriate target age groups is critical to ensure reaching rubella and measles elimination goals, begin - ning with an introductory RCV mass vaccination campaign. Progress toward achieving the GVAP goal of rubella elimina - tion in five of the six WHO regions by 2020 is not on track. To achieve this goal, the three regions with elimination targets need to interrupt transmission (European and Western Pacific regions) and maintain elimination (Region of the Americas), and two of three regions will need to establish and achieve the elimination target (African, Eastern Mediterranean, and South-East Asia regions) . Challenges to achieving rubella elimination goals include civil unrest that limits vaccine delivery, transmission in older populations, vaccine hesitancy in subpopulations, and weak health care service delivery with low routine vaccination coverage (7) . Optimal surveillance for rubella and CRS is essential to monitor the impact of rubella vaccine introduction and to verify progress toward rubella and CRS elimination goals (8) . This requires case-based surveillance, with all cases of febrile rash illness having serum specimens tested to determine if they are measles, rubella, or neither, as well as collecting oropharyngeal specimens to identify the rubella genotypes circulating worldwide. Outbreak investigations can identify immunity gaps, and responses can be targeted to interrupt transmission and achieve and maintain elimination. Surveillance for rubella and CRS and findings from outbreak investigations guide program managers to monitor progress, focus resources to address gaps, and document elimination. The findings in this report are subject to at least one limi - tation. The quality of surveillance for rubella is suboptimal. Although rubella and measles surveillance are integrated, rubella generally is a milder disease than measles, and infection is subclinical in 30%50% of cases (1); therefore surveillance Summary What is already known about this topic? Rubella virus infection is a leading vaccine-preventable cause of birth defects. In 2011, the World Health Organization (WHO) updated guidance on the preferred strategy for introduction of rubella-containing vaccine into national routine immunization schedules, including an initial vaccination campaign for children aged 9 months14 years. Global immunization partners have set targets to eliminate rubella and congenital rubella syn-drome in at least five of the six WHO regions by 2020. What is added by this report? During 20002106, rubella-containing vaccine was introduced in 53 countries, including 20 introductions after 2012. By December 2016, 152 (78%) of 194 countries were using the vaccine. These introductions and increased rubella vaccine coverage globally resulted in a decrease in reported rubella cases from 670, 894 cases in 2000, to 94, 277 cases in 2012, to 22, 361 cases in 2016. Elimination of rubella and congenital rubella syndrome was verified in the WHO Region of the Americas in 2015, and 33 (62%) of 53 countries in the European Region have now eliminated endemic rubella and congenital rubella syndrome. What are the implications for public health practice? To accelerate rubella elimination and control goals, a strong commitment to introduce rubella-containing vaccine and to achieve high rubella vaccination coverage in routine immuniza-tion services is needed in all countries. Countries and international partners should use the opportunity of measles elimination activities to achieve rubella elimination, through continued improvement of routine immunization services, vaccination campaign quality, and rubella and congenital rubella syndrome surveillance. is much less likely to detect rubella than measles. Despite use of standard case definitions, surveillance quality varies among countries, limiting comparisons of surveillance data. Because integrated surveillance for measles and rubella is less sensitive for rubella, surveillance for CRS serves to complement the data to improve the monitoring of rubella disease. The increase in the number of countries introducing RCV into national immunization schedules and eliminating endemic rubella virus transmission and the achievement of rubella elimination in the Region of the Americas, demonstrate progress toward global rubella control and elimination goals. Rubella and measles elimination efforts are synergistic; for example, RCV introduction catch-up campaigns, using a combined measles-rubella vaccine, also address measles immunity gaps. The path forward to reach regional rubella elimination goals is highlighted in recommendations from the Measles and Rubella Global Strategic Plan 20122020 Midterm Review (7) and requires continued improvement of routine immunization services, vac-cination campaign quality, and rubella and CRS surveillance. Morbidity and Mortality Weekly Report 1260 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and PreventionConflict of Interest No conflicts of interest were reported. 1Global Immunization Division, Center for Global Health, CDC; 2Department of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland. Corresponding author: Gavin B. Grant, gbgrant@cdc. gov, 404-639-8806. References 1. W orld Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec 2011; 86: 30116. 2. W orld Health Organization. Global vaccine action plan. Geneva, Switzerland: World Health Organization; 2012. http: //apps. who. int/iris/ bitstream/10665/78141/1/9789241504980_eng. pdf? ua=1 3. G rant GB, Reef SE, Dabbagh A, Gacic-Dobo M, Strebel PM. Global progress toward rubella and congenital rubella syndrome control and elimination20002014. MMWR Morb Mortal Wkly Rep 2015; 64: 10525. https: //doi. org/10. 15585/mmwr. mm6437a54. W orld Health Organization. Immunization surveillance, assessment, and monitoring. Data statistics and graphics by subject. Geneva, Switzerland: World Health Organization; 2017. http: //www. who. int/immunization/monitoring_surveillance/data/en/ 5. W orld Health Organization. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. Geneva, Switzerland: World Health Organization; 2003. http: //apps. who. int/iris/ bitstream/10665/68334/1/WHO_V-B_03. 01_eng. pdf? ua=1 6. P an American Health Organization. Elimination of rubella and congenital rubella syndrome in the Americas. Washington, DC: Pan American Health Organization; 2015. http: //www. paho. org/hq/ index. php? option=com_content&view=article&id=10801%3A2015-elimination-rubella-congenital-syndrome-americas&catid=6648%3Afact-sheets&Itemid=40721&lang=en 7. W orld Health Organization. Measles and rubella global strategic plan 20122020 midterm review. Geneva, Switzerland: World Health Organization; 2016. 8. W orld Health Organization. Framework for verifying elimination of measles and rubella. Wkly Epidemiol Rec 2013; 88: 8999. Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1261 US Department of Health and Human Services/Centers for Disease Control and PreventionAnnouncement World Day of Remembrance for Road Traffic Victims  November 19, 2017 In October 2005, the United Nations General Assembly adopted a resolution to mark the third Sunday in November each year as World Day of Remembrance for Road T raffic Victims to honor persons killed or injured in road crashes, recognize their families and communities, and pay tribute to the emergency crews, police, and medical professionals who deal with the traumatic aftermath of road deaths and injuries. * Road traffic injuries are the ninth leading cause of death worldwide and the leading cause of death among persons aged 1529 years (1) . Approximately 1. 25 million persons die each year on the worlds roads, and 20 million to 50 million sustain nonfatal injuries (1) . Although 90% of road traffic deaths occur in low-income and middle-income countries (1), approximately 100 persons die and thousands more are injured in motor vehicle crashes every day in the United States (2) . A 2016 CDC study found that, among 19 high-income countries, the United States had the most motor vehicle crash deaths per 100, 000 persons and per 10, 000 registered vehicles, the second highest percentage of deaths involving alcoholimpaired driving, and the third lowest use of front seat belts (3) . Recent trends do not show evidence of improvement. In 2016, a total of 37, 461 persons were killed in road traffic crashes in the United States, a 5. 6% increase from 2015 (2) . The U. S. Department of T ransportation and the National Safety Council have joined with partners, including CDC, to launch the Road to Zero Coalition, with the goal of eliminating U. S. traffic deaths by 2050 (4) . In the United States alone, implementing proven effective strategies to prevent road traffic deaths can save thousands of lives and hundreds of millions of dollars (3) . A new Road Safety Annual Report released by the Organisation for Economic Co-operation and Development * https: //www. worlddayofremembrance. org. provides a global perspective. It outlines specific recommenda - tions, potential numbers of lives saved, and potential economic losses prevented in International Road T raffic and Accident Database member and observer countries (5) . CDC supports United Nations and World Health Organization measures to dedicate 20112020 as the Decade of Action for Road Safety. The program was launched in May 2011 in approximately 100 countries, with the goal of preventing 5 million road traffic deaths globally by 2020. The United Nations is committed to measures to halve the number of global road traffic deaths and injuries by 2020 as one of its Sustainable Development Goals (http: //www. un. org/sustainabledevelopment/sustainable-development-goals/) . Strategies to support victims and survivors and a guide for non - governmental organizations are available at http: //www. who. int/violence_injury_prevention/publications/road_traffic/ngo_guide/en/. References 1. W orld Health Organization. Global status report on road safety 2015. Geneva, Switzerland: World Health Organization; 2015. http: //www. who. int/violence_injury_prevention/road_safety_status/2015/en/ 2. N ational Center for Statistics and Analysis. 2016 fatal motor vehicle crashes: overview. Washington, DC: US Department of T ransportation, National Highway T raffic Safety Administration, National Center for Statistics and Analysis; 2017. https: //crashstats. nhtsa. dot. gov/Api/Public/ ViewPublication/812456 3. S auber-Schatz EK, Ederer DJ, Dellinger AM, Baldwin GT. Vital signs: motor vehicle injury preventionUnited States and 19 comparison countries. MMWR Morb Mortal Wkly Rep 2016; 65: 6727. https: //doi. org/10. 15585/mmwr. mm6526e1 4. N ational Highway T raffic Safety Administration. US DOT, National Safety Council launch Road to Zero coalition to end roadway fatalities. Washington, DC: US Department of T ransportation, National Highway T raffic Safety Administration; 2016. https: //www. nhtsa. gov/press-releases/us-dot-national-safety-council-launch-road-zero-coalition-end-roadway-fatalities 5. I nternational T ransport Forum. Road safety annual report 2017. Paris, France: OECD Publishing; 2017. http: //www. oecd-ilibrary. org/transport/ road-safety-annual-report-2017_irtad-2017-en Morbidity and Mortality Weekly Report 1262 MMWR / November 17, 2017 / V ol. 66 / No. 45 US Department of Health and Human Services/Centers for Disease Control and PreventionErrata Vol. 66, No. SS-19 In the Surveillance Summary Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas  United States, on page 8, the title of Table 2 should have read  TABLE 2. Number and age-adjusted rate per 100, 000 persons for drug overdose deaths, by sex, race/ethnicity, intent of death, and age group, for metropolitan and nonmetropolitan counties of residence  National Vital Statistics System, United States, 19992015. *Vol. 66, No. 42 In the report Rapid Laboratory Identification of Neisseria meningitidis Serogroup C as the Cause of an Outbreak  Liberia, 2017, on page 1145, the figure title was not included in the printed version of this report. The figure title should have read FIGURE. Date of onset of outbreak cases (N = 31), by laboratory and outcome status  Liberia, 2017. *Morbidity and Mortality Weekly ReportMMWR / November 17, 2017 / V ol. 66 / No. 45 1263 US Department of Health and Human Services/Centers for Disease Control and PreventionQuickStats FROM THE NATIONAL CENTER FOR HEALTH STATISTICS Percentage* of Adults Aged 2064 Years Whose Blood Cholesterol Was Checked by a Health Professional in the Past 12 Months, by Race/Ethnicity  National Health Interview Survey, United States, 2011 and 2016 020406080100 Total Hispanic White, non-HispanicBlack, non-HispanicAsian, non-HispanicPercentage2011 2016 Race/Ethnicity * W ith 95% confidence intervals shown with error bars.  B ased on a positive response to the question During the past 12 months, have you had your blood cholesterol checked by a doctor, nurse, or other health professional?  C ategories shown are for non-Hispanic respondents who selected one racial group; respondents had the option to select more than one racial group. Hispanic origin refers to persons who are of Hispanic ethnicity and might be of any race or combination of races. Only selected individual groups shown in graph. Total bar based on all adults aged 2064 years.  Estima tes are based on household interviews of a sample of the civilian, noninstitutionalized U. S. population and are derived from the National Health Interview Survey Sample Adult component. The percentage of adults aged 2064 years who had a blood cholesterol check by a health professional in the past 12 months increased from 56. 0% in 2011 to 61. 7% in 2016. From 2011 to 2016, there was an increase in the percentage of adults with a blood cholesterol check among Hispanic (49. 0% to 56. 7%), non-Hispanic white (56. 8% to 62. 5%), non-Hispanic black (60. 8% to 65. 6%), and non-Hispanic Asian (55. 8% to 63. 0%) persons. In both years, non-Hispanic black adults were more likely than non-Hispanic white adults to have had a blood cholesterol check, and Hispanic adults were the least likely to have had a blood cholesterol check. Source: National Health Interview Survey, 2011 and 2016 data. https: //www. cdc. gov/nchs/nhis. htm. Reported by: Michael E. Martinez, MPH, MHSA, MEMartinez@cdc. gov, 301-458-4758; Emily P. Zammitti, MPH; Maria A. Villarroel, PhD. ISSN: 0149-2195 (Print) The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit MMWR s free subscription page at https: //www. cdc. gov/mmwr/mmwrsubscribe. html. Paper copy subscriptions are available through the Superintendent of Documents, U. S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800. Readers who have difficulty accessing this PDF file may access the HTML file at https: //www. cdc. gov/mmwr/index2017. html. Address all inquiries about the MMWR Series, including material to be considered for publication, to Executive Editor, MMWR Series, Mailstop E-90, CDC, 1600 Clifton Rd. , N. E. , Atlanta, GA 30329-4027 or to mmwrq@cdc. gov. All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U. S. Department of Health and Human Services. References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U. S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in MMWR were current as of the date of publication. Morbidity and Mortality Weekly Report","summary":""}